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Abstract 
Glucose is the principal source of energy for the mammalian 
cells. The energy independent transport of glucose down its 
concentration gradient is mediated by members of the facilitative 
glucose transporter (GLUT) family. Six members of the GLUT family 
have been described so far. They are named as GLUT 1-5 and GLUT 
7 while GLUT 6 is a psuedogene that is not expressed at protein 
level. 
It has long been recognized that cancer cells have increased 
rates of glucose metabolism compared with healthy cells. Glucose 
transporters also have been shown to be overexpressed in many 
human cancer cells. The glucose transporters may help provide extra 
energy for the growth of cancer cells. 
Antisense nucleic acids are formulated to be complementary to 
glucose transporter gene and thus are potential blockers of 
transcription and translation by forming a hybrid duplex with the 
target nucleotide sequence. These antisense nucleic acids, when 
targeted to specific cancer cells, provide another approach to cancer 
therapy. However, the application of antisense nucleic acid is 
considerably limited by the low efficiency of their penetration into 
intact cells and their instability in serum-containing culture 
medium. In order to overcome this problem, chemically modified 
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oligonucleotides had been designed and liposome had been used to 
facilitate their delivery into the cells. 
In my project, antisense nucleic acids against GLUT 1 gene 
were designed and transfected into HL-60 cells. The inhibition of 
HL-60 cell proliferation, change in GLUT 1 mRNA level and change 
in glucose uptake rate were measured. 
Sense, antisense and scramble oligonucleotides were 
synthesized. By Methythiazol tetrazoUum bromide (MTT) assay, it 
was found that 10 mM was the optimal concentration for inhibiting 
the proliferation of HL-60 cells and the time required for the 
maximum inhibition was about 24 hours. 
Among the four regions selected, which include 5，untranslated 
region (141)，start codon (169)，coding region (750) and 3， 
untranslated region (1592), greatest antisense effect was resulted 
when oligonucleotide was designed at the start codon. 
Oligonucleotide length was another important criteria for 
designing antisense oligonucleotides since it would affect the uptake 
efficiency. It was shown that both 15-mer and 30-mer 
oligonucleotides showed similar inhibition effect. In order to test 
their uptake efficiency, an oligonucleotide uptake assay was 
performed by labeling the oligonucleotides with p2p] radioactive 
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substance. The results showed that the difference between their 
uptake efficiency was below 20%. 
Another factor affecting the uptake efficiency was the use of 
liposome. When 10 i^M of AS169 oligonucleotides was encapsulated 
into cationic liposome before incubated with the cells, the 
oligonucleotide uptake efficiency increased more the 30%. This was 
resulted when the ratio ofDNA to liposome was 1:5. 
In order to decrease the degradation of oligomers by nuclease 
present in the culture medium, the oligonucleotides were modified to 
produce phosphorothioated oligonucleotides in which the oxygen 
atom at the phosphate backbone was replaced by a sulfur atom. The 
effect was improved by 10% when the oligomers were modified. 
Another method to decrease nuclease attack was to use serum-free 
medium since the nuclease was frequently present in the serum. 
All these inhibitions of cell proliferation were detected in 
antisense oligonucleotides but not in negative, sense and scramble 
control. This demonstrated that the effect was specific and the 
oligonucleotides were not toxic to the cells. 
In Northern Hybridization, mRNA of 2.8 kb in size was probed 
and the result showed that mRNA level of GLUT 1 decreased when 




In another set of experiment, antisense RNA was expressed by 
expression vector pRc/CMV. GLUT 1 cDNA was cloned into the 
vector at sense or antisense orientation. Transfection of the vector 
into HL-60 cells was performed by using the liposome. Over 50% of 
inhibition of cell proliferation was reached after incubating for 72 
hours. Northern analysis also showed a drastic decrease in GLUT 1 
mRNA level. 
To confirm the decrease in GLUT 1 protein, glucose uptake 
assay were performed. In order to prevent degradation of glucose by 
the cell after uptake, tritium labeled 2-deoxyglucose was used to 
perform the assay. For both antisense oligonucleotide and expressed 
antisense nucleotides, a significant decrease in glucose uptake in 







1.1 FflpJlitativft Glucose Transporter Family 
The energy independent transport of glucose across the plasma 
membrane is carried out by members of the facilitative glucose 
transporter (GLUT) family. This family belongs to a much larger 
superfamily of 12 transmembrane segment transporters (Fig. 1.1). 
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Fig. 1.1 Model for the orientation of mammalian facilitative 
glucose transporters in the membrane. The 12 transmembrane 
helices are shown as boxes and are numbered 1-12. Invariant residues are noted 
using the single-letter abbreviations for the amino acids with polar residues 




Up to now, cDNAs encoding six structurally-related proteins 
with the properties of facilitative glucose transporters have been 
isolated and characterized. The human genes encoding these 
proteins are named GLUT 1-5 and GLUT 7. In addition to these six 
functional facilitative glucose tranporters, an expressed facilitative 
glucose transporter pseudogene-like sequence (GLUT 6) has been 
identified in human tissues. This sequence is part of a ubiquitously 
expressed mRNA, but does not encode a functional protein. 
These six human glucose transporters exhibit 39-65% sequence 
identity and three general characteristics are shared among them. 
First, all six of these proteins have been shown to transport glucose 
using heterologous expression systems but they transport glucose 
with different efficiencies and kinetics (Pessin, et al., 1992). Second, 
the isoforms exhibit a tissue-specific distribution OVtueckler，1994) 
and a single cell-type often expresses two or more different isoforms 
(Table 1.1). Third, the expression of most of the GLUT genes is 
developmentally regulated (Nagamatsu, et al.，1994). 
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Isoform Tissue distribution Functions . 
QLUT 1 many fetal and adult basal glucose and increased 
tissues; abundant in human supply for growing/dividing 
red ceUs and many ceUs 
immortalized ceU Unes  
GLUT2 “ hepatocytes, pancreatic P> high-capacity, low-affinity 
cells，kidney transport  
GLUT 3 high expression in brain, basal transport in many 
also located in many human human ceUs; uptake from 
tissues cerebral fluid into brain  
parenchymal ceUs  
GLUT4 heart, skeletal muscle rapid increase in transport 
in response to elevated 
blood insuUn  
GLUT 5 mainly in intestine, lesser intestinal absorption of 
amounts in acUpocyte, fructose 
muscle and brain  
GLUT 7 hepatocytes and other mediates flux across 
gluconeogenic tissues endoplasmic reticulum  
membrane  
Table 1.1 Tissue distribution and functions of facilitative 
glucose transporters (adapted from Mueckler, 1994) 
1.2 Sequence and characterization of GLUT 
Among the six isoforms, GLUT 1 appears to be the most 
ubiquitously distributed, hence given the name of "house-keeping 
isoform” (Younes, 1996). The cDNA sequence of GLUT 1 is shown in 
Fig. 1.2. The size of full length cDNA is 2.8 kb. The initiation codon 
is the first ATG triplet located at position 180. An open reading 
frame starts from this ATG and continues to position 1658. This 
isoform is also called the erythrocyte, brain or HepG2-type glucose 
transporter. The purification of GLUT 1 from human erythrocyte 
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membranes showed that GLUT 1 comprises 5% of the total red cell 
membrane, by far the highest concentration density for any glucose 
transporter. GLUT 1 is expressed in many fetal and adult 
mammalian tissues and many cancer cell types (Bell, et al, 1990). 
1 TAGTCGCGGG TCCCCGAGTG AGCACGCCAG GGAGCAGGAG ACCAAACGAC GGGGGTCGGA 
6 1 GTCAGAGTCG CAGTGGGAGT CCCCGGACCG GAGCACGAGC CTGAGCGGGA GAGCGCCGCT 
1 2 1 CGCACGCCCG TCGCCACCCG CGTACCCGGC GCAGCCAGAG CCACCAGCGC AGCGCTGCCA 
1 8 1 TGGAGCCCAG CAGCAAGAAG CTGACGGGTC GCCTCATGCT GGCTGTGGGA GGAGCAGTGC 
2 4 1 TTGGCTCCCT GCAGTTTGGC TACAACACTG GAGTCATCAA TGCCCCCCAG AAGGTGATCG 
3 0 1 AGGAGTTCTA CAACCAGACA TGGGTCCACC GCTATGGGGA GAGCATCCTG CCCACCACGC 
3 6 1 TCACCACGCT CTGGTCCCTC TCAGTGGCCA TCTTTTCTGT TGGGGGCATG ATTGGCTCCT 
4 2 1 TCTCTGTGGG CCTTTTCGTT AACCGCTTTG GCCGGCGGAA TTCAATGCTG ATGATGAACC 
4 8 1 TGCTGGCCTT CGTGTCCGCC GTGCTCATGG GCTTCTCGAA ACTGGGCAAG TCCTTTGAGA 
5 4 1 TGCTGATCCT GGGCCGCTTC ATCATCGGTG TGTACTGCGG CCTGACCACA GGCTTCGTGC 
6 0 1 CCATGTATGT GGGTGAAGTG TCACCCACAG CCTTTCGTGG GGCCCTGGGC ACCCTGCACC 
6 6 1 AGCTGGGCAT CGTCGTCGGC ATCCTCATCG CCCAGGTGTT CGGCCTGGAC TCCATCATGG 
7 2 1 GCAACAAGGA CCTGTGGCCC CTGCTGCTGA GCATCATCTT CATCCCGGCC CTGCTGCAGT 
7 8 1 GCATCGTGCT GCCCTTCTGC CCCGAGAGTC CCCGCTTCCT GCTCATCAAC CGCAACGAGG 
8 4 1 AGAACCGGGC CAAGAGTGTG CTAAAGAAGC TGCGCGGGAC AGCTGACGTG ACCCATGACC 
9 0 1 TGCAGGAGAT GAAGGAAGAG AGTCGGCAGA TGATGCGGGA GAAGAAGGTC ACCATCCTGG 
9 6 1 AGCTGTTCCG CTCCCCCGCC TACCGCCAGC CCATCCTCAT CGCTGTGGTG CTGCAGCTGT 
1 0 2 1 CCCAGCAGCT GTCTGGCATC AACGCTGTCT TCTATTACTC CACGAGCATC TTCGAGAAGG 
1 0 8 1 CGGGGGTGCA GCAGCCTGTG TATGCCACCA TTGGCTCCGG TATCGTCAAC ACGGCCTTCA 
1 1 4 1 CTGTCGTGTC GCTGTTTGTG GTGGAGCGAG CAGGCCGGCG GACCCTGCAC CTCATAGGCC 
1 2 0 1 TCGCTGGCAT GGCGGGTTGT GCCATACTCA TGACCATCGC GCTAGCACTG CTGGAGCAGC 
1 2 6 1 TACCCTGGAT GTCCTATCTG AGCATCGTGG CCATCTTTGG CTTTGTGGCC TTCTTTGAAG 
1 3 2 1 TGGGTCCTGG CCCCATCCCA TGGTTCATCG TGGCTGAACT CTTCAGCCAG GGTCCACGTC 
1 3 8 1 CAGCTGCCAT TGCCGTTGCA GGCTTCTCCA ACTGGACCTC AAATTTCATT GTGGGCATGT 
1 4 4 1 GCTTCCAGTA TGTGGAGCAA CTGTGTGGTC CCTACGTCTT CATCATCTTC ACTGTGCTCC 
1 5 0 1 TGGTTCTGTT CTTCATCTTC ACCTACTTCA AAGTTCCTGA GACTAAAGGC CGGACCTTCG 
1 5 6 1 ATGAGATCGC TTCCGGCTTC CGGCAGGGGG GAGCCAGCCA AAGTGATAAG ACACCCGAGG 
1 6 2 1 AGCTGTTCCA TCCCCTGGGG GCTGATTCCC AAGTGTGAGT CGCCCCAGAT CACCAGCCCG 
1 6 8 1 GCCTGCTCCC AGCAGCCCTA AGGATCTCTC AGGAGCACAG GCAGCTGGAT GAGACTTCCA 
1 7 4 1 AACCTGACAG ATGTCAGCCG AGCCGGGCCT GGGGCTCCTT TCTCCAGCCA GCAATGATGT 
1 8 0 1 CCAGAAGAAT ATTCAGGACT TAACGGCTCC AGGATTTTAA CAAAAGCAAG ACTGTTGCTC 
1 8 6 1 AAATCTATTC AGACAAGCAA CAGGTTTTAT AATTTTTTTA TTACTGATTT TGTTATTTTT 
1 9 2 1 ATATCAGCCT GAGTCTCCTG TGCCCACATC CCAGGCTTCA CCCTGAATGG TTCCATGCCT 
1 9 8 1 GAGGGTGGAG ACTAAGCCCT GTCGAGACAC TTGCCTTCTT CACCCAGCTA ATCTGTAGGG 
2 0 4 1 CTGGACCTAT GTCCTAAGGA CACACTAATC GAACTATGAA CTACAAAGCT TCTATCCCAG 
2 1 0 1 GAGGTGGCTA TGGCCACCCG TTCTGCTGGC CTGGATCTCC CCACTCTAGG GGTCAGGCTC 
2 1 6 1 CATTAGGATT TGCCCCTTCC CATCTCTTCC TACCCAACCA CTCAAATTAA TCTTTCTTTA 
2 2 2 1 CCTGAGACCA GTTGGGAGCA CTGGAGTGCA GGGAGGAGAG GGGAAGGGCC AGTCTGGGCT 
2 2 8 1 GCCGGGTTCT AGTCTCCTTT GCACTGAGGG CCACACTATT ACCATGAGAA GAGGGCCTGT 
2 3 4 1 GGGAGCCTGC AAACTCACTG CTCAAGAAGA CATGGAGACT CCTGCCCTGT TGTGTATAGA 
2 4 0 1 TGCAAGATAT TTATATATAT TTTTGGTTGT CAATATTAAA TACAGACACT AAGTTATAGT 
2 4 6 1 ATATCTGGAC AAGCCAACTT GTAAATACAC CACCTCACTC CTGTTACTTA CCTAAACAGA 
2 5 2 1 TATAAATGGC TGGTTTTTAG AAACATGGTT TTGAAATGCT TGTGGATTGA GGGTAGGAGG 
2 5 8 1 TTTGGATGGG AGTGAGACAG AAGTAAGTGG GGTTGCAACC ACTGCAACGG CTTAGACTTC 
2 6 4 1 GACTCAGGAT CCAGTCCCTT ACACGTACCT CTCATCAGTG TCCTCTTGCT CAAAAATCTG 
2 7 0 1 TTTGATCCCT GTTACCCAGA GAATATATAC ATTCTTTATC TTGACATTCA AGGCATTTCT 
2 7 6 1 ATCACATATT TGATAGTTGG TGTTCAAAAA AACACTAGTT TTGTGCCAGC CGTGATGCTC 
2 8 2 1 AGGCTTGAAA TCGCATTATT TTGAATGTGA AGGGAA 
Fig. 1.2 Full-length cDNA sequence of GLUT 1 (adapted from 
Mueckler, et al” 1985) 
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1.3 Overexpression of GLUT 1 in human cancer cells 
Malignant cells show an increased glucose uptake and 
utilization when compared to their benign counterparts. This uptake 
is mediated by glucose transporters. The expression and activity of 
which have been found to be regulated by oncogenes and growth 
factors OMischoulon, et a/., 1992; Merrall, et al” 1993). 
GLUT 1 mRNA and protein have been found in rat brain, 
endothelial ofthe human blood-brain barrier and ofthe liver, human 
erythrocytes, HepG2 hepatic carcinoma cell line, rat kidney, rat 
mammary gland, and placenta, including fetal membranes 
(Birnbaum, et al” 1986; Camps, et al” 1994). 
The presence of mRNA in different GLUTs in human tumors 
was widely reported (Fukumoto, et al” 1988; Fukumoto, et al” 1989; 
Kayano, et al., 1988) and a significant increase in the abundance of 
mRNA for GLUT 1 was appeared in cancers of esophagus, colon, and 
pancreas O"amamoto, et al” 1990). In addition, GLUT 1 was also 
shown to be overexpressed in many human cancer cell lines (Bell, et 
al.，1990). The apparent overexpression of GLUT 1 in human cancer 
cells suggests an important role in tumor biology. 
Cancer cells, as growing indefinitely, require greater energy 
source than the normal cells. Glucose, as a basic energy source, is 
speculated to provide extra energy to the dividing cancer cells. 
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Decreasing the energy supply to cancer cells may lead to a reduction 
in cancer cell number. This can be done by decreasing the number of 
glucose transporter at the cell membrane via the inhibition of GLUT 
gene expression. 
1.4 Inhibition of gene expression bv antisense nucleic acid 
Down-regulating or specifically turning off the expression of 
individual gene represents a powerful tool for studies of its biological 
role in both in vitro cell cultures and in vivo in animal or plant 
models. This should also have great potential for therapeutic 
applications as in the search for more selective antiviral or 
antineoplasmic drugs. 
Antisense nucleic acids offer the potential to block the 
expression of specific genes within cells. The development of effective 
antisense techniques will allow researchers to address questions 
about gene function and may also lead to new therapies for many 
human diseases. 
If the nucleic acid sequence encoding a protein is known, 
molecules can be designed to bind the corresponding mRNA, thereby 
inhibiting the production of the protein (Fig. 1.3). The nucleotide 
sequence ofDNA or RNA that contains the information for the amino 
acid sequence of the protein is called the sense strand. In double-
7 
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stranded DNA, the other nucleotide sequence is complementary to 
the sense strand and is called the antisense strand. It is possible to 
synthesize antisense-strand nucleotides that bind the sense strand of 
RNA or DNA with a high degree of specificity. These antisense 
nucleotides can block somatic-gene products encoded by our own 
genome. 
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Fig. 1.3 Blockade of translation by antisense nucleotide. 
Normal gene transcription of DNA into mRNA is followed by translation of 
mRNA into protein. Antisense nucleotides complementary to a portion of mRNA 
bind to the mRNA and prevent further translating process (adapted from Askari, 
et al., 1996). 
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1.5 Tvt>es of antisense nucleic acids 
The application of antisense technology to the suppression of 
the gene expression can be presented by two methods. Method 1 
involves the suppression of constitutive gene expression, using 
plasmid vectors or virus vectors (Denhardt, 1992). In this method, 
the expressed antisense nucleic acid is used primarily to suppress 
the expression of genes on the host genome more or less perpetually. 
Method 2 involves suppression of transient gene expression using 
. antisense oligonucleotides synthesized chemically by automated 
synthesizer (Akhtar, et al” 1992). In terms of prospective 
applications to medicine, method 1 provides a system for gene 
therapy whereas method 2 is more appropriate for development of 
pharmaceutical agents. 
1.5.1 Nuclear expression ofRNA bv engineered antisense 
genes 
In the constitutive system for repressing gene expression, 
general protocols for manipulation of recombinant DNA can be used. 
The principle of regulation by antisense RNA is simple in that RNA 
that is complementary to the target mRNA is introduced into the 
cells, resulting in specific RNA : RNA duplexes being formed by base 
pairing between the antisense substrate and the target mRNA. 
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This can be achieved by the introduction and expression of an 
antisense gene sequence, that is, one in which part or all of the 
normal gene sequences are placed in a vector in inverted orientation 
so that the “wrong" strand is transcribed into a noncoding antisense 
RNA that then hybridizes with the target mRNA and interferes with 
its expression. Such an antisense expression vector can be 
constructed by standard procedures and introduced into the cells by 
any of the normal means of transferring DNA, such as transfection, 
electroporation, microinjection, o r， i n case of viral vectors by 
infection. The type of transformation and choice of vector will 
determine whether expression is transient or stable, the level, 
timing, inducibility or tissue specificity of the antisense inhibition. 
Depending upon the system, inhibition is sometimes observed at the 
level of splicing of the primary transcript, transport of the mature 
mRNA into the cytoplasm, or translation of the mRNA (Denhardt, 
1992). 
1.5.2 Antisense oligonucleotides 
Antisense oligonucleotides are short sequences of single-
stranded DNA, usually less than 30 nucleotides in length, 
synthesized by chemical means in vitro, and are complementary to a 
specific intracellular target, normally the mRNA. Because antisense 
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oligonucleotides are produced by chemical method, they must be 
applied either externally to cells or via microinjection, and as a 
consequence, their effects will normally be transient. 
1.6 Use of antisense oligomers in cell culture svstem 
Antisense oligonucleotides have been used predominantly in 
animal cell culture systems. Cell culture provides a readily 
manipulable system for examining relevant biological effects of 
antisense oligomers. The possible therapeutic potential of normal 
and modified oligomers can be evaluated in a controlled environment 
using small amounts of oligomers. 
When experiments with tissue culture cells are initiated, 
several important considerations must be applied. These relate to 
the stability of the oligomers in the tissue culture system and 
interactions between the oligomers and the cells, including uptake 
and possible toxicity. 
The tissue culture system chosen to determine the effects of 
the antisense oligonucleotides should be optimized to utilize a 
minimum number of cells, since the volume of tissue culture media 




1.7 Modification of antisense oligonucleotides 
Unmodified oligonucleotides are internalized by cells and can 
interact with intracellular targets. However, it is a common 
observation that normal oligonucleotides are rapidly attacked and 
degraded by nucleases present in the serum component of culture 
medium, which can only be partly overcome by heat inactivation 
(Akhtar, et aZ., 1991). Moreover, after the uptake by cells, 
oligonucleotides are subject to continuing degradation within cells, 
though at a greatly reduced rate compared with their attack in the 
culture medium. The dual aims of improving both cell uptake and 
resistance to nucleases were tackled by synthesizing modified 
oligomers. 
Several different approaches have been used to modify normal 
oligomers: modification of the phosphodiester linkage, change from 
p- to a-anomer, attachment of additional groups, and attachment of 
chemically active groups. Yields vary widely and some derivatives, 
such as poly-L-lysine oligomers, tend to aggregate and may yield 
false estimates of concentration; other, such as 
oligomethylphosphonates, may have low solubility (Pilowsky, et al., 
1994). Phosphorothioates involve the presence of a sulfur residue 
instead of an oxygen residue linked to the phosphorus atom of the 
nucleotide backbone (Fig. 1.4). These derivatives are more resistant 
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to many types of nucleases (Stein, et al” 1988) than the normal 
oUgonucleotides. 
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Fig. 1.4 The structure of a phosphorothioated oligomer 
t 
(adapted from Akhtar, et aL, 1992). : � 
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Since modified oUgomers in which the phosphodiester Unkage 
is altered are designed to be resistant to nucleases or more 
permeable to uptake by ceUs, they can frequently be used at lower 
concentrations than normal oUgonucleotides to produce the same 
effect in a given assay; alternatively, when used at the same 
concentration, they will inhibit to a greater extent. 
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Replacement of phosphorus oxygen by a methyl group or sulfur 
atom generates chirality, since four different groups are attached to 
the phosphorus atom OVIurray, et al., 1992). Since synthesis is not 
stereospecific, each modified oligonucleotide will be a heterogeneous 
mixture of molecules. Little is known about the influence of chirality 
on hybridization. If only one of these molecules is truly active, the 
potency of the active species would be diluted by contamination with 
the less active or inactive forms. 
In order to compare the uptake efficiency of modified 
oligonucleotides with the unmodified one, it is advantageous to have 
a modified oligomer with a free 5，-OH group, or other groups suitable 
for labeling. 
1.8 Length and sequence selection of antisense oligomers 
Length is an important parameter to consider when designing 
antisense oligonucleotides. Length below 20-mers is a good choice on 
both practical and theoretical grounds. They are relatively easy to 
synthesize，and recognition at the level of 12 to 15 bp provides 
uniqueness in the range of 8-500 million bp; i.e., a 15-bp with unique 
sequence is likely to be found only once in 8-500 million bp of DNA. 
Studies with oligonucleotides of different chain lengths have 
indicated that 8-mers can be effective in inhibition and that much 
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larger oligomers, e.g. 21-mers, may be less effective, perhaps because 
of reduced solubility or permeability OMarcus-Sekura, 1988). 
In general, increase in oligonucleotide length will increase its 
specificity but the uptake efficiency will be decreased. So, it is 
important to make a balance between these two factors. 
Since antisense oligonucleotides appear to operate by 
hybridization arrest of translation, oligonucleotides that are 
antisense to the 5，and 3，noncoding regions are generally less 
effective than those antisense to translated regions. Sequences with 
5，end complementary to the start site and overlapping the initial 
methionine or those beginning at the initial methionine and 
extending over the first few additional codons appear to be the most 
effective (Leonetti et al” 1993). 
1.9 Controls for measuring antisense effect 
Antisense in high concentrations can display toxicity or have 
non-specific effects. It is therefore important to have the appropriate 
controls. One possible solution is to use a sense oligonucleotide as the 
control. A sense oligonucleotide has the same length as an antisense 
oligonucleotide and the same sequence as the homologous segment of 
mRNA and therefore cannot bind to it. One major potential risk with 
this strategy is that the sense oligonucleotide might have a very 
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different base composition to the antisense oligonucleotide, resulting 
in different intracellular base concentrations when the 
oligonucleotides are degraded (Wagner，1994). Since different bases 
might cause different metaboUc effects, it is better to use a jumbled 
sequence that has the same base composition as the antisense 
oligonucleotide. Alternatively, a sequence with only a few 
mismatches may be used. A mismatch of only one base will cause a 
decrease in hybridization efficiency of around 500-fold (Pilowsky, et 
al” 1994). Newly created sequences may hybridize to unintended 
mRNA. To some extent, this can be prevented by checking control 
sequences on gene data bases. 
1.10 Internalization and targeting of oligonucleotides 
One ofthe main problems in using synthetic oligomers is to get 
a sufficient number of molecules into the cells and prevent hydrolysis 
before they reach their target. Despite the presence of putative 
receptors at the cell surface C^akubov, et al.，1989)，it seems that 
oligomers are not internalized very efficiently. Much interest has 
been devoted to develop tools allowing protection of antisense 
oligomers against serum nuclease degradation, efficient transfer 
across the plasma membrane, and the possible targeting to cells 
expressing specific determinants at their surface. Chemical 
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conjugation of oligonucleotide with poly(L-lysine) (Lemaitre, et al., 
1987) or acridine (Toulme, et al” 1986) enhance cellular uptake and 
stability, and these benefits reveal an increased inhibitory effect on 
gene expression. The same approach has been successfully used in 
vitro with oligonucleotides conjugated with peptide, fatty acid and 
cholesterol (Rothenberg, et ah, 1989). 
However, therapeutic application of the antisense technology 
currently seems to be inadequate in the in vivo situation, where the 
biological reaction parameters are governed mainly by the body, the 
biological instability of the antisense molecules leads to an 
impractical and costly treatment. Thus, the effective clinical use of 
this new class of compounds relies on the development of an optimal 
delivery system. One of the more promising approaches is the use of 
liposomes as a carrier system. 
Liposomes are a broadly applicable and exciting drug delivery 
system. Liposomes are microscopic closed vesicles composed of 
bilayered phospholipid membranes surrounding aqueous spaces in 
which various drugs, antibiotic, antitumor agents, hormones, and 
viruses can be entrapped and delivered to the target within the cells. 
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1.11 Possible action mechanisms of antisense nucleotides 
ActuaUy, the mechanism of antisense action is poorly 
understood. It is proposed that this inhibition can be direct or quite 
indirect due to interference in the nuclei or the cytoplasm of the celLs :( 
'• > 
CFig. 1.5). The hybridization of the oligomer can change/the mRNA 
structure and inhibit spUcing or nucleocytoplasmic transport. The i 
^ 1 f 
mRNA oUgonucleotide duplex can be recognized by RNase H and 
I .t 
subsequently the mRNA can be uegraded. When located at the 5，end 
of mRNA, the oUgomer can inhibit the >Unding of translation 
( ‘ ] . 
initiation factors, the oligomers can also directly inhibit the 
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translation ofthe mRNA hyl ribosomes (Kawasaki, etal” 1996). 
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Fig. 1.5 Possible action mechanisms of antisense oligomers 
(adapted from Leonetti, et al., 1993). 
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1.12 Clinical applications of antisense approach 
Although much of the work on oligonucleotides has been 
carried out in cell culture, their successful application in obtaining 
therapeutic antisense effects will undoubtedly require extensive 
animal work before clinical application in humans is ever 
contemplated. A suitable formulation for the administration of 
oligonucleotides to animal models and eventually human subjects 
will be required. 
OUgonucleotides, rather like peptide and protein drugs, are 
susceptible to enzymatic hydrolysis and are unlikely to be effective 
by oral administration. Any approach to the delivery of 
oligonucleotides would need to ensure that the macromolecule is 
delivered intact to its intracellular site of action. Stability of 
oligonucleotides in intra- and extracellular compartments will be an 
important criterion in the design of effective delivery systems. 
Probably the major site of degradation following intravenous 
administration of oligomers will be in blood. Hence, if oligomers can 
be sufficiently protected from degradation in this compartment 
either by structural modifications or by a suitable delivery system 




Apart from approaches that can improve the biological 
stability of antisense compounds, delivery strategies that can 
enhance cellular uptake, aid efflux from endosomal compartments, 
or enable some control over the intracellular distribution will prove 
critical in the effective use of oligonucleotides as therapeutic agents 
in the future. 
1.13 Aim ofthe proiect 
As the overexpressed GLUT 1 in cancer cells may provide 
extra energy for their indefinite growing, any method that can 
inhibit / reduce the expression of GLUT 1 may provide a potential for 
cancer therapy. The aim of my project is to use antisense nucleotides 
against GLUT 1 gene to inhibit the expression of GLUT 1 and to see 
whether it can inhibit the growth of HL-60 leukemia cells. Both 
oligonucleotides and expressed nucleotides were used for the study. 
Condition is optimized by changing the oligonucleotide length and 
concentration, using the liposomes, selecting the target sequence and 
modifying the oligonucleotide structure. 
The antisense effect will be monitored by measuring the 
change in the percentage inhibition of HL-60 cell proliferation, 
GLUT 1 mRNA level and glucose uptake rate by HL-60 cells. 
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Materials and Methods 
2.1 Materials 
2.1.1 Cell line and culture medium 
2.1.1a Cell line 
The parental HL-60 population was kindly provided by 
Prof. K N Leung (Biochemistry Department, CUHK). HL-60 is a 
promyelocytic leukemia cell line. These cells were continuously 
maintained in suspension and showed lymphoblast like morphology. 
An inoculum of 10^  viable cells/ml in RPMI 1640 medium with 10% 
serum will increase 3- to 4-fold in 4 days. In every passage, 2 x 10® 
cells were seeded in 75 cm^ plastic flasks (Corning, U.S.A.) and 
cultured in a 5% CO2 / 90% air atmosphere in 20 ml of RPMI 1640 
medium at 37°C. The media were supplemented with 10% fetal calf 
serum. 
2.1.1b Culture medium 
RPMI 1640 medium (Sigma Chemical Company) in powder 
form was dissolved in 900 ml of distilled water. The pH was adjusted 
to 7.2 with lN sodium hydroxide. Two grams of sodium bicarbonate 
was added. After dissolved, additional water was added to bring the 
solution to a volume of 1 litre. The solution was then sterilized by 
filtration using a membrane with a porosity of 0.22 microns. One 
22 
Materials and Methods 
millilitre of filtered medium was incubated at 37°C，5% CO2 for 24 
hours to test the sterilization. The sterilized plain medium was 
stored at 4°C. Fetal calf serum (GibcoBRL) was aliquoted in 50 ml 
volume and stored at -20°C. 
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2.1.2 Reagents and Buffers 
2.1.2a Phosphate-Buffered Saline (PBS) 
PBS was prepared by dissolving 8 g of sodium chloride, 0.2 g of 
potassium chloride, 1.44 g of sodium hydrogen phosphate, and 0.24 g 
of potassium hydrogen phosphate in 900 ml of distilled water. The 
pH was adjusted to 7.4 with hydrochloric acid. Additional water was 
added to bring the solution to final volume of 1 litre. The solution 
was then sterilized by autoclaving. 
2.1.2b 50X TAE Buffer 
It was prepared by dissolving 242 g of Tris base in 57.1 ml of 
glacial acetic acid and 100 ml of 0.5M EDTA (pH 8.0). The solution 
was made to final volume of 1 litre by distilled water. 
2.1.2c Tris-EDTA (TE) Buffer 
TE buffer was prepared by mixing 1 ml of 100 mM EDTA (pH 
8.0) with 10 ml of 100 mM Tris Cl. The solution was made to final 
volume of 100 ml and sterilized by autoclaving. 
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2.1.2d MTT solution 
It was prepared by dissolving 100 mg of MTT (methylthiazol 
tetrazolium bromide) into 20 ml of distilled water. The solution was 
then filtered through Whatman filter paper to remove any 
undissolved crystal and stored at 4°C. 
2.1.2e Lipofectin Reagent 
Lipofectin Reagent is a 1:1 (w/w) liposome formulation of the 
cationic lipid N-[l-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium 
chloride (DOTMA), and dioleoyl phosphotidylethanolamine (DOPE). 
This liposome can interact with DNA to form a lipid-DNA complex 
and help mediate the transport of DNA into the cells. The 
concentration of Lipofectin Reagent was 1 |Xg/ml and the solution 
was stored at 4°C. 
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2.1.3 Reagents for Northern Analvsis 
2.1.3a DEPC-treated water fO.1% DEPC) 
One millilitre of diethyl pyrocarbonate (DEPC) was added to 1 
litre of distilled water. The mixture was shaken vigorously for 
several times and then sterilized by autoclaving. 
2.1.3b 20X Standard Saline Citrate (SSC) 
It was prepared by dissolving 175.3 g of sodium chloride and 
88.2 g of sodium citrate in 900 ml of distilled water. The pH was 
adjusted to 7.0 with 10N sodium hydroxide. Additional distilled 
water was added to make the solution to final volume of 1 litre and 
the solution was sterilized by autoclaving. 
2.1.3c 20X SSPE 
It was prepared by dissolving 175.3 g of sodium chloride, 27.6 g 
of hydrated sodium dihydrogen phosphate and 7.4 g ofEDTA in 900 
ml of distilled water. The pH was adjusted to 7.4 with 10 N sodium 
hydroxide. The solution was made to final volume of 1 litre by 




2.1.3d 10X Formaldehyde gel-running buffer 
It was prepared by dissolving 23.12 g of MOPS, Na (3-[N-
Morpholino]propanesulfonic acid]) and 3.4 g of sodium acetate into 
10 ml of 0.5 M EDTA (pH 8.0). Then, 300 ml of distilled water was 
added and the pH was adjusted to 7.0 with glacial acetic acid. The 
solution was made to final volume of 500 ml by distilled water and 
sterilized by filtration through 0.22 pim filter. 
• •-: 
2.1.3e Formaldehyde gel-loading buffer 
To prepare formaldehyde gel-loading buffer, 25 mg of 
bromophenol blue and 25 mg of xylene cyanol FF were added into 5 
ml of 100% glycerol and 100 i^l of 100 mM EDTA (pH 8.0). The 
solution was made to final volume of 10 ml with DEPC-treated water 
and stored at -20�C. 
2.1.3f Prehvbridization buffer 
To prepare 40 ml of prehybridization buffer, the following 
reagents were mixed: 20 ml of formamide (Amresco), 2 ml of 100X 
Denhart，s solution (2 % bovine serum albumin [Fraction V，Sigma], 
2% Ficoll [Type 400，Sigma], 2% polyvinylpyrrolidone [Molecular 
Biology Reagent, Sigma]), 12 ml of 20X SSPE, 2 ml of 10% SDS, 0.4 
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ml of Salmon sperm DNA (10 mg/ml, denatured at 95°C for 5 
minutes), 3.6 ml of DEPC-treated water. The solution was stored at 
-20�C. 
2.1.3g Hybridization buffer 
To prepare 40 ml of hybridization buffer, the following 
reagents were mixed: 20 ml of formamide, 12 ml of 20X SSPE, 2 ml 
of 10% SDS, 0.4 ml of Salmon sperm DNA, 5.6 ml of DEPC-treated 
water. The solution was stored at -20°C. 
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2.2 Methods 
2.2.1 Svnthesis of oligonucleotides and phosphorothioated 
oligonucleotides 
The oligonucleotides were synthesized in our laboratory using 
the Gene Assembler Special machine (Pharmacia Biotech). 
Phosphorothioated oligonucleotides were synthesized by Beaucage 
Thiolating Reagent (Pharmacia Biotech) according to the procedure 
suggested by the manufacturer. To freshly prepare this antisense 
reagent, acetonitrile was dried over calcium hydride (CaH2) one day 
prior to use. The antisense line in Gene Assembler was cleaned 
thoroughly by rinsing with this dry acetonitrile. A clean, dry, empty 
amidite vial was filled with 5 ml of dry acetonitrile and the solution 
was pumped through the Unes to waste. Then, 500 mg of Beaucage 
Thiolating Reagent was dissolved in 50 ml of dry acetonitrile and 
was placed on the port. The line was purged with the purge program. 
Once started, a sulfur atom will be placed on the 3，phosphate 
linkage of each base. 
After synthesis, the crude oligonucleotides were purified by 
NAP-10 column (Sephadex G-25, Pharmacia). The purified 
oligonucleotides were collected by eluting the column with sterile 
distilled water and were stored at -20°C. 
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The following table shows the oligonucleotides synthesized 
against GLUT 1 gene:  
*Name of oligo- Sequence Remarks 
nucleotides synthe-
sized  
S141-15 5，CGTACCCGGCGCAGC 3，~~~15-mers,~~^~~^~~untranslated 
region  
AS141-15 5，GCTGCGCCGGGTACG 3, 15-mers, at 5， untranslated 
region  
R141-15 5，TAGCCGGCCCCGCAG 3， 15-mers, at 5， untranslated 
region  
"^169-15 "^，GCAGCGCTGCCATGG~3^  15-mers, around start codon 
"^169-15 5' CCATGGCAGCGCTGC"F" 15-mers, around start codon — 
"ll69-15 5，GGTAGCGCAGCTGCC^ 15-mers, around start codon _ 
S750-15 5，AGCATCATCTTCATC 3， 15-mers,~~within~~the~~coding 
region  
AS750-15 5，GATGAAGATGATGCT 3， 15-mers, within the coding 
‘ region  
R750-15 5，GAATTCCCTTATACC 3，“ 15-mers, within the coding 
region  
S1592-15 ^ ' AGCCAGCCAAAGTGA 3 ^ 15-mers, around 3' end  
AS1592-15 5，TCACTTTGGCTGGCT 3， ‘ 15-mers, around 3，end 
R1592-15 5，GAATACCGGACGAAC 3， 15-mers, around 3，end  
S141-21 5，CGTACCCGGCGCAGCC 21-mers,~~at~~b'~~"untranslated 
AGAGC 3， region  
AS141-21 5' GCTCTGGCTGCGCCGG 21-mers, at 5， untranslated 
GTACG 3， region  
R141-21 5，TAGCCGGCCCCGCGGG 21-mers, at 5' untranslated 
TTGTG 3， region  
‘ S169-21 5，GCAGCGCTGCCATGGA 21-mers, around start codon 
GCCCA 3， 
AS169-21 5，TGGGCTCCATGGCAGC 21-mers, around start codon 
GCTGC 3， 
R169-21 5' GGTAGCGCAGCTGCCT 21-mers, around start codon 
GGCCT 3， 
S750-21 5，AGCATCATCTTCATCCC 21-mers, within the coding 
GGCC 3， region  
AS750-21 5，GGCCGGGATGAAGATG 21-mers, within the coding 
ATGCT 3， region  
R750-21 5，GAATGTCGCCGGTTGA“ 21-mers, within the coding 
GAAGG 3， region  
S1592-21 5，AGCCAGCCAAAGTGAT~ 21-mers, around 3' end 
AAGAC 3， 
AS1592-21 5，GTCTTATCACTTTGGC~~ 21-mers, around 3' end 
TGGCT 3， 
R1592-21 5，TGTTATCTCGTGATCGC 21-mers, around 3，end 
TTGC 3， 
"S169-S —5，GCAGCGCTGCCATGG 3， 15-mers, phosphorothioated 
"AS169-S 一 5 ， C C A T G G C A G C G C T G C 3， 15-mers, phosphorothioated 
"R169-S 5, GGTAGCGCAGCTGCC 3， 15-mers, phosphorothioated 一 
• * S • sense; AS - antisense; R- random sequence (scramble) 
The number indicates the position within the fuU length cDNA with the first base pair 
of start codon (ATG) designed as number 180. 
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2.2.2 Cloning of human GLUT1 cDNA into pRc/CMV 
expression vector at sense and antisense orientation 
2.2.2a Primer designed for cloning ofsense and antisense 
GLUT1 cDNA 
Human GLUT 1 cDNA clone was kindly provided by Dr. B. 
Thorens (University of Lausanne, Switzerland). This clone of full 
length of 2.5 kb was originally cloned into the BamHI cloning site of 
the pGEM3 vector. To clone into pRc/CMV vector, sense and 
antisense cDNA insert was first amplified by Polymerase Chain 
Reaction. A pair of primers (Forward: 5， 
TAGGGCAAGCTTCTGAAGTGTACCCGGAAAAGG 3'; Reverse: 5， 
TAGGGCGCGGCCGCGAAAAGTGATCAGGTTCAT 3，） was 
synthesized to produce cDNA insert in sense orientation. Another 
pair of primers (Forward: 5， 
TAGGGCGCGGCCGCCTGAAGTGTACCCGGAAAA 3，； Reverse: 5， 
TAGGGCAAGCTTGAAAAGTGATCAGGTTCATTT 3，） was 
synthesized to produce cDNA insert in antisense orientation. These 
two pairs of primers flanked the coding region of GLUT 1 to give a 
full length cDNA of 2.5 kb. An end clamp sequence ofTAGGGC was 
added in the beginning of both forward and reverse primers and two 
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cloning sites, Hind III and Not /, were also included in the forward 
and reverse primers, respectively. 
2.2.2b Isolation ofsense and antisense GLUT 1 clone bv PCR 
PCR was performed with 40 ng of plasmid DNA in a total 
volume of 50 i^l containing IX PCR buffer (Pharmacia Biotech), 200 
[iM dNTP mix (Pharmacia Biotech), 0.5 i^M of each of forward and 
reverse primer and 2.5 U of Taq Polymerase (Pharmacia Biotech). 
PCR was carried out by a programmable thermocycler QAJ Research, 
Inc.) with the following program. 
Step 1 94°C 5 minutes 
Step2a 95�C 36 seconds 
Step 2b 50°C 36 seconds 
Step 2c 72°C 1 minute and 30 seconds 
Step 3 34 more cycles from step 2a to 2c 
Step 4 72°C 10 minutes 
2.2.2c Restriction Digestion 
DNA restriction digestion was carried out in a total volume of 
20 \il containing IX One-Phor-All buffer (Pharmacia Biotech), 5 U of 
HindlIl and Not I (Pharmacia Biotech), 1 [ig of PCR product or 
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vector DNA and sterile double-distilled water. The digestion was 
performed at 37°C for two hours. After the digestion, the enzyme 
were heat-inactivated at 85°C for 30 minutes and then cooled to 
room temperature. 
2.2.2d Purification ofRestriction Digested DNA 
After restriction digestion, both the insert and vector was 
subject to purification. The DNA was electrophoresed in 1% TAE 
agarose gel. The gel containing the target DNA was excised and put 
in microfuge tube. This target DNA was purified by GENECLEAN 
kit (BCH Medical Supplies Co.). According to the protocol suggested 
by the manufacturer, the gel was weighed and 3 volumes of 6 M 
sodium iodide was added to it. The tube was incubated at 55^C water 
bath for 10 minutes until the gel was dissolved. Ten microlitre of 
GLASSMILK was added and the mixture was incubated at room 
temperature for 15 minutes with occasional shaking. The mixture 
was centrifuged at 10000 x g for 10 seconds. The supernatant was 
discarded and the pellet was washed with 200 i^l of ice-cold New 
Wash for three times. To elute the bound DNA, 20 i^l of sterile 
distilled water was added to resuspend the pellet and the mixture 
was incubated at 55�C for 10 minutes. After incubation, the mixture 
was subject to centrifugation at 10000 x g for 20 seconds. The 
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supernatant was saved and DNA was quantified by electrophoresis 
in 1% TAE agarose gel. 
2.2.2e DNA Ligation 
The cohesive-end DNA ligation was performed by T4 DNA 
Ligase (1 U/^ il, GibcoBRL). The molar ratio of insert to vector was 
3:1. The 20 \il of ligation reaction mixture contained 1 1^ o fT4 DNA 
Ligase, 100 ng of total DNA (insert and vector), 4 i^l of 5X ligation 
buffer (GibcoBRL) and sterile distilled water. The ligation was 
carried out at 16°C overnight. 
2.2.2f Preparation of competent bacterial cells for 
transformation 
A single bacterial cell colony (Escherichia coli JM109) was 
inoculated in 1.5 ml of LB medium supplemented with ampicillin 
(lOOmg/ml) and the culture was incubated in a shaking air-bath set 
at 37�C overnight with gentle shaking at 250 r.p.m.. Then 250 i^l of 
the overnight culture was transferred to 25 ml of fresh LB medium 
supplemented with ampicillin and the culture was further incubated 
at 37°C for about 3 hours until reaching the log phase. The cells were 
collected by centrifugation at 3000 r.p.m. (Beckman rotor 20-2) for 10 
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minutes at 4�C, the cell pellet was resuspended in one-third volume 
of the original culture of RF1 buffer (100 mM RbCl, 50 mM 
MnCl2.4H2O, 30 mM potassium acetate, 10 mM CaCl2.2H2O, 15% w/v 
glycerol, pH 5.8, filtered-sterile) and incubated on ice for 20 minutes 
before harvesting by centrifugation at 3000 r.p.m. (Beckman rotor 
20-2) for 15 minutes at 4�C. The cell pellet was then resuspended in 
1/12.5 volume ofthe original culture ofRF2 buffer (10 mM MOPS, 10 
mM RbCl, 75 mM CaCl2.2H2O, 15% w/v glycerol, pH 6.8，filtered-
sterile). The cells were chilled on ice for another 15 minutes and 
aliquoted into 500 d^ fraction. The competent cells were then rapidly 
frozen by liquid nitrogen and stored at -70°C. 
2.2.2g Plasmid DNA Transformation (Sambrook，et al” 1989) 
Frozen competent cells were thawed on ice. The ligated 
plasmid DNA was added into the competent cells and the tubes were 
swirled gently to mix their contents. The mixture was incubated on 
ice for 30 minutes and then the cells were heat shocked at 42�C for 
exactly 90 seconds. After heat-shock, the tube was immediately put 
on ice for 2 minutes. Eight hundred microliter of LBC medium (LB 
medium with 20 mM glucose) was added to the tube. The tubes were 
then transferred to a shaking incubator set at 37^C. The culture was 
incubated for 45 minutes. Finally, the transformation mixture was 
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plated on LB-plates containing 5 mg of ampicillin. The plates were 
left at room temperature until the culture has been absorbed. The 
plates were incubated at 37°C overnight. 
2.2.3 Large scale preparation of plasmid DNA 
After transformation, two bacterial colonies, each containing 
the transformants with sense or antisense respectively were isolated 
and inoculated into 250 ml of LB medium with 25 mg of ampicillin. 
The culture was allowed to grow in 37�C air-bath with shaking at 
250 r.p.m.. The bacterial cells were harvested by centrifugation at 
7000 X g for 10 minutes at 4�C. The following procedure was 
suggested by the QIAGEN Midi-prep kit manufacturer. The cell 
pellet was suspended in 4 ml of P1 buffer (50 mM Tris-HCl, pH 8.0; 
10 mM EDTA; 10 i^g/ml RNase A). Then, 4 ml of P2 buffer (200 mM 
NaOH, 1% SDS) was added. After mixing gently, the mixture was 
incubated at room temperature for 5 minutes. Then, 4 ml of ice-cold 
P3 buffer (3 M potassium acetate, pH 5.5) was added. The mixture 
was mixed gently and incubated on ice for 15 minutes. The mixture 
was centrifuged at 12000 x g for 30 minutes at 4°C and the 
supernatant was saved. A QIAGEN-tip 100 column was equilibrated 
with 4 ml of QBT buffer (750 mM NaCl; 50 mM MOPS, pH 7.0; 15% 
ethanol; 0.15% Triton X-100). The supernatant was applied to the 
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column and was allowed to run through the column by gravity. Then, 
the column was washed twice with 10 ml of QC buffer (1.0 M NaCl; 
50 mM MOPS, pH 7.0; 15% ethanol) and the DNA was eluted with 5 
ml of QF buffer (1.25 M NaCl; 50 mM Tris-HCl, pH 8.5; 15% 
ethanol). Then, 3.5 ml of isopropanol was added for precipitation. 
The solution was centrifuged at 12000 x g for 30 minutes at 4�C. The 
DNA pellet was washed with 2 ml of ice-cold 70% ethanol, air-dried 
and dissolved in appropriate amount of sterile distilled water. The 
amount of plasmid prepared was measured by DNA/RNA Calculator 
(GeneQuant, Pharmacia Biotech). The plasmids with sense and 
antisense strands can then be used to transfect into the HL-60 cells. 
2.2.4 Formation of Lipofectin-encapsulated oligonucleotides 
Referring to the protocol given by the manufacturer of 
Lipofectin Reagent, HL-60 cells at 2x105 were seeded in 35 cm^ 
tissue culture flask with serum-supplemented medium. The cells 
were incubated at 37°C, 5% COg for 24 hours until the cells were 40-
60% confluent. Then, solution A and B were prepared. Solution A 
contained 2 i^g of oligonucleotide with 100 d^ of serum-free medium. 
Solution B contained 10 i^g of Lipofectin Reagent with 100 i^l of 
serum-free medium. Solution B, after being allowed to stand at room 
temperature for 45 minutes, was mixed with solution A. The mixture 
37 
Materials and Methods 
» 
was incubated at room temperature for 15 minutes. The cells were 
washed once with 2 ml of serum-free medium. For each tube 
containing the Lipofectin Reagent-oligo complex, 0.8 ml ofserum-free 
medium was added. The complex was overlaid onto the cells. The 
cells were incubated at 37�C，5% CO2 for appropriate period and the 
antisense effect was monitored. 
2.2.5 pP1-labeled oligonucleotides uptake assav (Wickstrom, 
1992) 
Oligonucleotides were 5，labeled with 1 i^Ci of [a-32P]dCTP 
(3000 Ci/mmol, Amersham) by 1 i^l of T4 kinase (1 U/^ il, GibcoBRL). 
The labeled oligonucleotides were purified by NucTrap purification 
column (Stratagene, U.S.A.). The column was first equilibrated by 70 
1^ ofTE buffer (pH 8.0). [a-^^P]dCTP that had not been incorporated 
into the oligonucleotides was removed by applying the reaction 
mixture into the equilibrated column. The radiolabeled 
oligonucleotide was then eluted by 70 i^l ofTE buffer. 
For each time point, 5xl0^ cpm of [5'-^^P]oligonucleotide was 
added to 5xl0^ HL-60 cells in 4 ml of RPMI 1640 without serum. 
Each sample was incubated at 37�C for 0，4，8，20，26, 30 hours 
respectively and then sedimented at 1200 x g for 5 minutes. The 
supernatant was removed and saved. The cells were washed twice 
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with PBS and the wash was saved. The cell pellet was lysed with 0.1 
ml of PBS with 1% SDS and then extracted with 0.1 ml of phenol. 
After centrifugation, the aqueous phase was removed and the phenol 
was extracted with another 0.1 ml of distilled water. The culture 
medium supernatant, the cell wash and the aqueous extracts were 
analysed by scintillation counting. 
Another set of uptake assay was done after using Lipofectin to 
mediate the uptake. 
2.2.6 Methods to monitor antisense effect 
2.2.6a MTT assav 
5 X 10^  cells/well were seeded in 100 pJl of RPMI medium in a 
96-well culture plate. Oligonucleotides (with or without 
encapsulation by Lipofectin) were diluted to the appropriate 
concentration with culture medium to a final volume of 50 fxl and 
. ‘ 
were added to the cell suspension. The cells were incubated at 37°C, 
5% CO2. Thirty microlitre of MTT solution (5 mg/ml) was added to 
the well and incubated at 37^C for 1 hour. Then, 50 i^l of acidified 
(0.04N HC1) 10% SDS was added and further incubated for 30 
minutes. A hundred microlitre of isopropanol was added and 
incubated for 15 minutes to dissolve any crystals formed during 
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reduction of MTT by living cells. The plate was shaken briefly and 
absorbance at 540 nm was read by a microplate reader (Bio-Rad, 
Model 3550). 
2.2.6b Northern Analvsis (Sambrook, et al” 1989) 
(i)Preparation of radiolabeled probe 
The radiolabeled DNA probe was synthesized using the Ready-
To-Go DNA labelling kit (Pharmacia Biotech). According to the 
procedure suggested by manufacturer, 20 i^l of distilled water was 
added to the reaction mix (dATP, dGTP, dTTP, 4-8 units of Klenow 
Fragment, random oligodeoxyribonucleotides) and stand on ice for 5 
minutes. Thirty nanograms of DNA (in volume of 25 i^l) was 
denatured at 95�C for 5 minutes. The denatured DNA was 
immediately put on ice for 2 minutes and centrifuged briefly. The 
reaction mix was mixed with denatured DNA, 5 |il of [a-^^P]dCTP (50 
I 
i^Ci, 3000 Ci/mmol) and 50 i^l of distilled water. The contents were 
incubated at 37�C for 30 minutes. 
An equilibrated NucTrap push column (Stratagene, U.S.A.) 
was used to remove the unincorporated radioactive nucleotide by 
applying the reaction mixture into the column. The radiolabeled 
probe was eluted by TE buffer. 
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(ii> Isolation of total RNA from HL-60 cells 
AU the apparatus involved were autoclaved and rinsed by 0.1% 
DEPC to remove any RNase. All reagents needed were autoclaved or 
filtered. 
HL-60 ceUs were sedimented for 5 minutes at 1200 x g. The 
medium was discarded and the cells were washed twice with PBS. 
For 1x10? cells, 1 ml ofTRIzol Reagent (GibcoBRL, U.S.A.) was used. 
The cells were lysed by TRIzol Reagent by repetitive pipetting. The 
samples was then incubated at room temperature for 5 minutes to 
permit the complete dissociation of nucleoprotein complexes. Then, 
0.2 ml of chloroform was added per 1 ml of TRIzol Reagent. The 
mixture was shaked vigorously for 15 seconds and incubated at room 
temperature for 3 minutes. After centrifugation at 12000 x g for 20 
minutes at 4°C, the mixture was separated into a lower red phase, 
an interphase and a colorless upper aqueous phase. The aqueous 
phase which contained RNA was transferred into a new centrifuge 
* 
tube without disturbing the interphase. RNA was precipitated by 
adding 0.5 ml of isopropanol per ml of TRIzol Reagent and incubated 
at -20�C for 20 minutes. RNA pellet can be collected by centrifuging 
the tube at 13000 x g for 10 minutes. The resultant pellet was 
washed with cold 70% ethanol and air-dried. The pellet was 
dissolved into appropriate volume of 0.5% SDS. Pipetting and 
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incubation at 55�C were applied to help dissolve the RNA pellet. The 
RNA prepared was stored at -70�C. The integrity of RNA was 
monitored by electrophoresing by 1% TAE agarose gel in IX TAE 
buffer. The quantity of RNA loaded on each lane could also be 
adjusted by the result of this gel electrophoresis. 
(iii�Separation oftotal RNA bv electrophoresis and 
blotting onto a membrane 
One percent resolving gel was prepared by dissolving 0.4 g of 
agarose in 34 ml of DEPC-treated water. When cooling to 50�C，10X 
formaldehyde gel running buffer and formaldehyde were added to 
make the final concentration to be IX and 2.2 M, respectively. The 
sample could be prepared while the gel was setting. 
The sample contained the following components: 30-40 \ig of 
RNA (4.5 i^l), 2 Ml of 10X formaldehyde gel-running buffer, 3.5 i^l of 
i 
formaldehyde (37%), 10 [d of formamide. The sample was denatured 
at 65�C for 10 minutes. 2 1^ of formaldehyde gel-loading buffer (50% 
glycerol, 1 mM EDTA, pH 8.0, 0.25% bromophenol blue, 0.25% 
xylene cyanol FF, 0.5 mg/ml ethidium bromide in 0.1 M ammonium 
acetate) was added to the sample before loading into the wells of gel. 
The gel was running at 3-4 V/cm in formaldehyde gel-running buffer. 
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After electrophoresis, the gel was soaked into DEPC-treated 
water for 10 minutes by 4 times and then in 20X SSC for another 10 
minutes by 4 times. Meanwhile, a piece of Whatman 3 mm filter 
paper and a piece ofPVDF membrane (Immobilon-N, Millipore) with 
same size of the gel was prepared. A container was filled with 
transfer buffer, 20X SSC and a glass plate was put on top of the 
container to form a support. A long strip offilter paper was laid over 
the glass plate with both ends dipped into the buffer to form a bridge 
to allow the current flow. The gel was placed onto the filter up side 
down and then the PVDF membrane (prewetted by ethanol and 
rinsed by DEPC-treated water) was put on top of the gel. Any 
bubbles between the gel and membrane was removed using a glass 
TM 
rod. The edges of the gel were wrapped around with SaranWrap to 
prevent short circuit. The Whatman filter paper was put on top of 
membrane. A stack of paper towel and a 500 g weight were put on 
the top to give a pressure. The transfer of RNA was allowed to ！ 
I f 
proceed overnight. ^ 
Before removing the membrane from the gel, the position of 
wells was marked by a pencil. Then the membrane was soaked into 
6X SSC for 10 minutes. RNA was then cross-linked onto the 
membrane by baking the membrane at 80�C for 2 hours. 
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(iv�Prehvbridization of the Northern blot 
The blot prepared was put into a plastic box. The box was filled 
with prehybridization buffer until the blot was completely immersed 
( � 4 0 ml of prehybridization buffer for one membrane) • The contents 
were incubated in 42°C water bath overnight with shaking. 
(V�Hvbridization of the Northern blot 
After prehybridization, the buffer was replaced with 
hybridization buffer. The radiolabeled probe prepared was denatured 
at 100�C for 5 minutes and immediately added to the hybridization 
mixture (-40 ml of hybridization buffer for one membrane) . Then 
the system was incubated at 42°C overnight. 
After hybridization, the membrane was washed with low 
stringency wash buffer (IX SSC, 0.1% SDS) at room temperature for 
10 minutes followed by washing with high stringency wash buffer 
I 
(0.2X SSC, 0.1% SDS) for 10 minutes until about 5-10 counts per 
minute of radioactivity was obtained from a portable GM-counter. ^ 
TIvI 
The membrane was then wrapped with SaranWrap and an 
autoradiograph was established by exposing the membrane for 24 
hours to X-ray film at -70�C with an intensifying screen. The film 
was developed using a developer pC-ray developer, Type 2，Kodak) 
and fixing solution (liquid X-ray fixer and replenisher, Kodak). 
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2.2.6c pHldftoxvgl"^^g^ iiptake assav (Chan, et al” 1983) 
HL-60 cells (2 x 10^  cells/ml) were incubated in 35 mm culture 
dish in 0.5 ml of medium with 10% serum for 24 hours. The medium 
was removed and cells were washed twice with pre-warmed PBS. 
The cells were resuspended in 0.2 ml of medium. Then 0.2 ml of 2-
deoxy-D-PH]glucose (1 l^Ci/^ lmol) was added to the cells. The reaction 
mixture was further incubated at 37^C for 7 minutes. After which 
the reaction was terminated by washing the cells twice with ice cold 
10 mM 2-deoxy-D-glucose. The ceUs were then solubilized with 0.2 
ml of 0.1% Triton-X 100. The lysate was transferred to scintillation 
vials containing 2 ml ofTriton X-toluene scintillant and radioactivity 













3.1 Svnthesis of Oligonucleotides 
The yields of all oligonucleotides and phosphorothioated 
oligonucleotides synthesized were over 90% and the concentrations 
were between 651-874 i^g/ml as measured by the DNA/RNA 
Calculator (GeneQuant, Pharmacia Biotech). Oligonucleotides with 
random sequences were sent in the form of electronic mails to the 
National Centre for Biotechnology Information (NCBI) for homology 
search using the program BLASTN. The results of the homology 
search were then edited and printed (Fig. 3.1). No match was found 






Database: Non-redundant GenBank+EMBL+DDBJ+PDB sequences 












Query As Used Computed -— 
Strand MatID Matrix name Lambda K H Lambda K H 
+1 0 +5,-4 0.192 0.173 0.357 same same same 
-1 0 +5,-4 0.192 0.173 0.357 same same same 
Query 
Strand MatID Length Eff.Length E S W T X E2 S2 
+1 0 15 15 10.87 11 0 73 0.02147 
-1 0 15 15 10.87 11 0 73 0.02147 
Statistics: 
Query Expected Observed HSPs HSPs 
Strand MatID High Score High Score Reportable Reported 
+1 0 95(26.3bits) 70 (19.3 bits) 0 0 
-1 0 95 (26.3 bits) 70 (19.3 bits) 0 0 
Query Neighborhd Word Excluded Failed Successful Overlaps 
Strand MatID Words Hits Hits Extensions Extensions Excluded 
+1 0 8 384 12 0 372 0 
-1 0 8 527 16 0 511 0 
Database: Non-redundant GenBank+EMBL+DDBJ+PDB sequences 
Release date: June 14, 1997 
Posted date: 9:39 AM EDT Jun 14, 1997 
#oflettersindatabase: 492,175,625 
# of sequences in database: 321,573 
# of database sequences satisfying E: 0 
No. ofstates in DFA: 14 (14 KB) 
Totalsize ofDFA: 15 KB (64 KB) ！ 
Time to generate neighborhood: 0.00u 0.00s 0.00t Real: 00:00:00 
No. ofprocessors used: 4 
Time to search database: 6.18u0.62s6.80t Real: 00:00:02 
Total cpu time: 6.19u 0.63s 6.82t Real: 00:00:02 
Fig. 3.1 An example showing the homology search ofAS169 
(15-mers) with other deposited sequences in the Genebank 
and EMBL database by using the BLASTN server. 
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3.2 Multiple alignment of cDNA seauence ofGlucose 
Transporter isoforms 
To prevent non-specific binding of oligonucleotide to other gene 
product, the cDNA sequences of different GLUTs were aligned (Fig. 








10 20 30 40 50 
HUMGLUT1. SEQ 142 GTACCCGGCG CAGCCAGAGC CACCAGCGCA GCGCTGCCAT GGAGCCCAGC 191 
HUMGLUT2. SEQ 1 CACAAGAC*T GGAATT**CA GGA*TC*CA* CTAG*A*A** *ACAGAAGAT 50 
HUMGLUT3. SEQ 205 CCTAGATCTT TCTTG*AGA* TTGA*TTAG* TTA*A**G** **G*A*ACAG 254 
HUMGLUT4.SEQ 108 C*T*G*C**C *CTG*GCGT* **G*TCTT*T AA*AC*AG** *CC*T*GG** 157 
HUMGLUT5.SEQ 38 AA*GGA**T* AGCGGCACT* TG**CTTC** *A**AAG*** *****AACAG 87 
HUMGLUT7 . S5Q 83 C*GAT**TAC T*CTTGTCAA ACAA***A*C T*AAGAAG** *TCAGA*GA* 132 
60 70 80 90 100 
HUMGLUTl.SEQ 192 AGCAAGAAGC TGACGGGTCG CCTCATGCTG GCTGTGGGAG GAGCAGTGCT 241 
HUMGLUT2.SEQ 51 *AGGTC*CTG G***CCTGGT TT***CTG*C ATCACT*CT* TGCTG*GTTC 100 
HUMGLUT3.SEQ 255 *AGGTC*CC* CAG*TCTGAT AT*TGCCA*C A*A**T*CTA C*ATC*GCTC 304 
. HUMGLUT4.SEQ 158 TT*C*AC**A *AGGCTCCGA AGATGG*GAA C*CCCTCAGC AGCG****AC 207 
HUMGLUT5.SEQ 88 GATC***GCA ***A**AAG* GAGGC**AC* CT****CTT* CCCTG*CAAC 137 
HUMGLUT7.SEQ 133 TCGCTA*C*G CT***CTGTC G**AT*CG*C TTCACT*C** TGCTG*GTTC 182 
110 120 130 140 150 
HUMGLUTl.SEQ 242 TGGCTCCCTG CAGTTTGGCT ACAACACTGG AGTCATCAAT GCCCCCCAGA 291 
HUMGLUT2. SEQ 101 CTT*CAGT*T GGA*A**A*A TTGGTGTGAT CAATGCACC* CAA*AGGTA* 150 
HUMGLUT3. SEQ 305 *TT*CAAT*T GGC*ACAA*A CTGGGGTCAT CAATGCTCC* *AGAAGATC* 354 
HUMGLUT4.SEQ 208 * * * G A * * * * * GTCC***CTG TGTT*T***C G**GC*TGGC T * * * T G * * * T 257 
HUMGLUT5.SEQ 138 CCTGATAGCT GCC*****G* CATC*TTCCA GTATGGGT*C AA*GTGGCTG 187 
HUMGLUT7 . SEQ 183 CTT*CAGT*C GGA*A**A*A T*GGTGTGAT CAATGCACC* CAAGAGGTA* 232 
160 170 180 190 200 
HUMGLUTl.SEQ 292 AGGTGATCGA GGAGTTCTAC AACCAGACAT' GGGTCCACCG CTATGGGGAG 341 
HUMGLUT2.SEQ 151 TAA*ATCTC* CT*TAGAC*T GTTTT*GGTG TTCCA*TGGA TG*CC*AA*A 200 
HUMGLUT3.SEQ 355 TAAA*GAATT TATCAATA*A *CTTT***GG ACAAGGGAAA TGCCCCACCC 404 
HUMGLUT4.SEQ 258 TT*G*TA*A* CATTGGGGT* *T*A*TG*CC CTCAGA*GGT GAT**AAC** 307 
HUMGLUT5.SEQ 188 CT**C*A*TC CCCAGCACTG CT*AT*CA*C AAT*TT**AA TG*GACTT*C 237 
HUMGLUT7.SEQ 233 TAA*ATC*C* TT*TCGAC*T GTTTT*GGTG TTCCT*TGGA TG*CC*AAGA 282 
210 220 230 240 250 
HUMGLUTl.SEQ 342 AGCATCCTGC CCACCACGCT CACCACGCTC TGGTCCCTCT CAGTGGCCAT 391 
HUMGLUT2. SEQ 201 GCT***AACA A*TATGTTA* **A**GTACA GATGAA**GC *CACAAT*TC 250 
HUMGLUT3.SEQ 405 TCTGAGG*** TGCT****TC TCT*TG*TC* *T***TG*GG *CA*ATTTTC 454 
HUMGLUT4.SEQ 308 ***TA*AATG AG**GTG*** GGGG*G**AG G**C*TGAGG G*CCCAG*TC 357 
HUMGLUT5.SEQ 238 TATGGTAG*A **GGTGAAT* **TGGAAGA* *TCC**T*GA *GT**CTGTG 287 
HUMGLUT7 . SEQ 283 GCT*C*A*TA A*TATGACA* **ATGGCACA GACA***CAC TCA*A*T**C 332 
260 270 280 290 300 
HUMGLUTl.SEQ 392 CTTTTCTGTT GGGGGCATGA TTGGCTCCTT CTCTGTGGGC CTTTTCGTTA 441 
HUMGLUT2.SEQ 251 A*AC**AA*G AACCCA*AAC CAAC*C*T*G GG***A**AA GAGACT**GG 300 
. HUMGLUT3.SEQ 455 *G*CGGG*G* AT*AT*GGCT CCTTT***G* *GGAC*CTT* G*CAA*CGCT 504 
HUMGLUT4.SEQ 358 *A*CC**CCA **CAC*C*C* CCAC*CT**G GG*CC*CTC* G*GGC*A*CT 407 
HUMGLUT5.SEQ 288 G*C*GTAACC *T*TC****T **CCA*TTGG AGGGT*TAT* GGA*C*C*CC 337 
HUMGLUT7 . SEQ 333 ACCAG*ACA* AC*ACACCAG AC*C**GGGA AGAA*A*ACT GAAGGATC*G 382 
310 320 330 340 350 
HUMGLUTl.SEQ 4 42 ACCGCTTTGG CCGGCGGAAT TCAATGCTGA TGATGAACCT GCTGGCCTTC 4 91 
HUMGLUT2.SEQ 301 CAGCTGC*CA A*TAATC*CC ATGC*CTG*T CCC**TCTG* ATCCAG***T 350 
HUMGLUT3.SEQ 505 TTG**AGGC* *AATTCA*TG CTG**TG*C* ACC**TTGGC TG*CA*TGGT 554 
HUMGLUT4.SEQ 408 TTTC*G*G** *G*CAT**T* **CTCCT*CC *C**TGGTA* CA*CT*TCAG 457 ： 
HUMGLUT5.SEQ 338 TGGT*GGCCC *TT*GT**** AA*T*TGGC* GA*AAGGGGC CT**CTG*** 387 | 
HUMGLUT7.SEQ 383 CT*A*A*A*T *ACTAT*CTC *GGTCT***T CTG**TC*AG CT*T**AG*A 432 j 
360 370 380 390 400 
HUMGLUTl.SEQ 4 92 GTGTCCGCCG TGCTCATGGG CTTCTCGAAA CTGGGCAAGT CCTTTGAGAT 541 ‘ 
HUMGLUT2.SEQ 351 *CAGTT*GT* GAA*G*CT*C A*CA*TCTTT GGT**GTG*C TTGGG**C*C 400 
HUMGLUT3.SEQ 555 *GC*G*TTTA **GGAC**T* TAAAGTAGCT AA*TCGGTTG AAA*GCT*** 604 
HUMGLUT4.SEQ 458 TG*CTT*GAA G*AAA*G**C *A*GCT*GTC AACAATGTCC TGGCG*T*C* 507 
HUMGLUT5.SEQ 388 AACAA*ATAT *TTCT**C*T GCCTG***TC T*AATGGGA* G*AGCAGAG* 437 
HUMGLUT7.SEQ 433 *GCGGAATG* *CGC*TC*TT ***TGGTGGG TG*CTTGG*G A*AAACTCGG 482 
410 420 430 440 450 
HUMGLUTl.SEQ 542 GCTGATCCTG GGCCGCTTCA TCATCGGTGT GTACTGCGGC CTGACCACAG 591 
HUMGLUT2 . SEQ 401 A**TGGAAGA AT*AAAGC** *GT*A*TA*C AA**ATTCTG TCATTAGTT* 450 
HUMGLUT3.SEQ 605 c***GGT*GC TTGGTTA*TG G*C**TTCTG CGGACT*T** ACAGGTTTT* 654 
HUMGLUT4.SEQ 508 *GG*GG*AGC CT*ATGGG*C *GGC*AAC*C TGCTGC*TC* TATGAA*TGC 557 
HUMGLUT5.SEQ 438 CGCC*CATCA TTTGAGC*T* ****TAT*TC CAGACTTTTG G**GGA*T*T 487 
HUMGLUT7.SEQ 483 AAG****AAA *C*ATG**GG CTGCAAACAG CCT**CGTTG ACTGGAG*CC 532 
# Matched bases are denoted by * 
50 
Results 
460 470 480 490 500 
HUMGLUTl.SEQ 592 GCTTCGTGCC CATGTATGTG GGTGAAGTGT CACCCACAGC CTTTCGTGGG 641 
HUMGLUT2.SEQ 451 *AGCTC*CTT G***GGGT*T TCAA**T**G G***AT*TCA TA*A*T*ATA 500 
HUMGLUT3.SEQ 655 TGCC*A**TA ***TGGA*A* ATCTCGCCTA *TG**CTGCG GGG*GCCTTT 704 
HUMGLUT4.SEQ 558 T*A**C*TGG ACGA*TCC*C AT**GC*CC* ACT*AGGGCT GACATCA*** 607 
HUMGLUT5.SEQ 488 *TGCA*GTGT ATCT*CCAAC *TG*TCCCCA TGTA*TT**G GGAG*TG*CC 537 
HUMGLUT7.SEQ 533 T***GA**GG GTGT*CCAAA TT**G*CC*A GC*ATG*TCT *A*CAT**CT 582 
‘ 510 520 530 540 550 
HUMGLUTl.SEQ 642 GCCCTGGGCA CCCTGCACCA GCTGGGCATC GTCGTCGGCA TCCTCATCGC 691 
HUMGLUT2.SEQ 501 ATTGCT**A* GAAGCATATC AGGACTATAT TGT*GGCTA* *TTCAGG*CT 550 
HUMGLUT3.SEQ 7 0 5 *G*ACTCT** A**A**TGGG CA*C*TTG*T *GAA*TCTGG *GGC*CAGAT 754 
HUMGLUT4.SEQ 608 CTGG**CC** TGTACGTGGG *GA*ATTGCT CC*ACTCA*C *G*GGGG*** 657 
HUMGLUT5.SEQ 538 C*TAAAAA*C TG*G*GGGGC T**C**GG*G **GCC*CAGC ^ * T * ^ * * * A * 587 
HUMGLUT7.SEQ 583 *GAAGAA**G TATCAGGA*T *TACT*TGGG C*AA*TTCAG GA**GG*TC* 632 
560 570 580 590 600 
HUMGLUTl.SEQ 692 CCAGGTGTTC GGCCTGGACT CCATCATGGG CAACAAGGAC CTGTGGCCCC 741 
HUMGLUT2.SEQ 551 GGTTCCTA*G TATA*C*GTG AA**TGCTCC A*C*GCTCT* AG*G*AG*A* 600 
• HUMGLUT3.SEQ 755 *TTT*GTC*G *AAT*CAT*C TTGGGTCT*A AG*GCTATGG *C*CT**TA* 804 
HUMGLUT4.SEQ 658 **T**G*ACG CT*AACC*AC TGGC***T*T T*T*GGCATT ***ATCG*** 101 
HUMGLUT5.SEQ 588 TGTT*GCA** CTTG***C*C AG***T*T** TCTTCG*A*T **CCTTG*AA 637 
HUMGLUT7.SEQ 633 AAT*TACA*T ***GAAATT* *TCCGCACAC GCTG*GA*GA GC*GCTGGTA 682 
610 620 630 640 650 
HUMGLUTl.SEQ 742 TGCTGCTGAG CATCATCTTC ATCCCGGCCC TGCTGCAGTG CATCGTGCTG 7 91 
HUMGLUT2.SEQ 601 *TGGCACTTT TCATCAGC*G GC*ATC*T*A' C*GGCATTCT T**TAGT*A* 650 
HUMGLUT3.SEQ 805 **GGTT*T*C ****C*TCCT GCTATCCTA* AAAGTGCAGC *C*TCCAT*T 854 
HUMGLUT4.SEQ 708 A * G * * * * * G * *T*GGAG*C* C***T**G*A CTGCCAGCCT GTGGCCA*** 151 
HUMGLUT5.SEQ 638 ACG*AGATG* *TGGCCGA** C*G*T**GG* **ACCGG*GT *CC**C*GC* 687 
HUMGLUT7 . SEQ 683 CAT*AT**CA AC*GGGGA*A *CTGT**GTA *TA*TATCA* TCAAA*C*** 732 
660 670 680 690 700 
HUMGLUTl.SEQ 792 CCCTTCTGCC CCGAGAGTCC CCGCTTCCTG CTCATCAACC GCAACGAGGA 841 
HUMGLUT2.SEQ 651 ATTA*TG*T* TT**ATT*AT *TTGGG*AAT TATGATCTGT *GC**ATCCT 700 
HUMGLUT3.SEQ 855 TG*CCTGAAA GTCCC**ATT TTTGC**A*T AA**GA**AG AAG*G***A* 904 
HUMGLUT4.SEQ 758 *T*C*GG*** T*ACAGTG*T A*CTGC***C **GCAGCTGG T*CTGCT*CC 807 
HUMGLUT5.SEQ 688 *TGCAGCT** TTCT*CTG** *TT*****CC GAG*G*CC*A *GT**CT*CT 737 
HUMGLUT7 . SEQ 733 GGGC**GA*A ATTCATCAGG AAA*G*TAAC AC*TGGCCA* ATTTATTAAG 782 
710 720 730 740 750 
HUMGLUTl.SEQ 842 GAACCGGGCC AAGAGTGTGC TAAAGAAGCT GCGCGGGACA GCTGACGTGA 8 91 
HUMGLUT2.SEQ 701 *CTTG*CCTG TCTG****** G*GCC*TC** T*AGTCTCTG CTACT*T*TT 750 
HUMGLUT3.SEQ 905 TGCTAA*CAG *TCCTCCA** GGTT*TG*GG CAC*CA*GAT *TATC*CAAG 954 
HUMGLUT4.SEQ 808 CTT*T*TC** G****CCCC* GCT*CCTCTA CAT*ATCCAG AA*CT**A*G 857 
HUMGLUT5.SEQ 738 **TT*A*AAG **AGAC*AAG CGGCCGCCAA *AAA*CCCT* CAGACGC**C 787 
HUMGLUT7.SEQ 783 TCT*A*TCGG *TACCC*CCG C*CTTC*A*C CGCTATTCT* C*ATTTCCAC 832 
760 770 780 790 800 
. HUMGLUTl.SEQ 892 CCCATGACCT GCAGGAGATG AAGGAAGAGA GTCGGCAGAT GATGCGGGAG 941 
HUMGLUT2.SEQ 7 51 T*TG*CCAGA AAGCCCC*GA T*CCTTT*C* TCAA*TTAGA TGA*GAA*TC 800 
HUMGLUT3.SEQ 955 A*ATCC*GGA *AT*A*AGAT G**AGT*CA* *GAT*TCACA AGAAAA*C*A 1004 
HUMGLUT4.SEQ 858 GG*C**C*AG AA**AGTC** ***CGCCT** CAG*CTG*GC CGATGTTTCT 907 
HUMGLUT5.SEQ 788 G*GGCTGGGA CTCT*T*GAC *G***G*T*G CCGA*ATCCG *CA*GA***T 837 
HUMGLUT7.SEQ 833 * T G * A T C * * C A*C*TG*C*T *CCAT***T* TCGATG*TGA AGGTAAT*CA 882 j 
8 1 0 8 2 0 8 3 0 8 4 0 8 5 0 I 
HUMGLUTl.SEQ 942 AAGAAGGTCA CCATCCTGGA GCTGTTCCGC TCCCCCGCCT ACCGCCAGCC 991 
HUMGLUT2. SEQ 801 **AGCAAAAC AA*G*T**A* AAGAC**A*A GGATAT*ATG *TGT*ACCAA 850 ‘ 
HUMGLUT3.SEQ 1 0 0 5 GTC*CC**GC TAGAG**CTT TAGAG*GTC* AG*TA*CGAC *G*C*ATCAT 1054 
HUMGLUT4.SEQ 908 GGAGT*C*GG *TGAG***A* *GATGAGAAG CGGAAGCTGG *G**TG***G 957 
HUMGLUT5.SEQ 838 G**GCA*AG* AGGC*GC**G CT*CA**TC* GTG*TGAAGC TGTT**G*AT 887 
HUMGLUT7 . SEQ 883 **A*G*A**C TACAATCACT C*A*GGTTAT GA*GAA*TT* C**A*G*A*T 932 
860 870 880 890 900 
HUMGLUTl.SEQ 992 CATCCTCATC GCTGTGGTGC TGCAGCTGTC CCAGCAGCTG TCTGGCATCA 1041 
HUMGLUT2 SEQ 851 AGATA*T*AT *AAA**AGAA AAG*AAGAGA AG*AGCATC* AG**AGCAG* 900 
HUMGLUT3 SEQ 1055 ***TTC***T *TGC*CCA** *CTCT*A*CA G*TCTCTGG* ATCAATGCTG 1104 
HUMGLUT4 SEQ 958 GCCA**GTC* C T G C * C C A * * *C*T*GGCAG * * G T A C C * A C CGGCAGCC*C 1007 
HUMGLUT5.SEQ 888 GCG*TCGC*G CGCTG*CA** ***T*TCCAT *ATCGTC**C A T G * * * G G * C 937 
HUMGLUT7 . SEQ 933 *CAAGAA**A AAA*AT*AAA GT**AAAAGA A G * * G C * G A * A * * T T T C * T * 982 
# Matched bases are denoted by * 
51 
Results 
910 920 930 940 950 
HUMGLUT1 SEQ 1042 ACGCTGTCTT CTATTACTCC ACGAGCATCT TCGAGAAGGC GGGGGTGCAG 1091 SuMSu^ a'slo 0^1 *A*TCTCTA* AAT*C*GCT* TTC*C-AT* C*AGCT*CCG ACA*CCTATT 950 
HUMGLU^^slo 1105 TGTTCTAT*A -CAACAGGA -TCTT-AGG AT*CAGGT*T TCAA*A-CC 1154 HUMGLU^MIo 1008 TGATCA*TGC GGTCGTGCTG CA*CTG*G*C AGC-CTCT* T-CA*CA*T 1057 HUMGLU^ s^lo 938 *GCAGC*G*C GGGCGT*AA* G*T*T*TA** A*T^ CGC-A CCA*A*CT*C 987 HS??:SEQ 983 C?CTAA-GA GCTGCTGAGA T—AGATA CGAGATG*C* CTCCC***T* 1032 
‘ 960 970 980 990 1000 
HUMGLUT1 SEO 1092 CAGCCTGTGT ATGCCACCAT TGGCTCCGGT ATCGTCAACA CGGCCTTCAC 1141 HUMGLU^2'slo 951 *TAGTG*CAC TGATGCTGCA -TGG*TCAG CAAT*TTC*G GAAT*AATGG 1000 
MHMr^'u^MEO 1155 ATCTA-CCA CCAT*GG*GC G**TGTG*T* *ATACT-T*T TCA*TG*AGT 1204 
Z S u ^ M l o io58 GCTCT^T^C* -TATT*G*C CA-AT*TTC GAGACAGCAG G-TAGG*CA 1107 
H S ^ s l E Q 9^8 *f*AGC*CCG GC-TGC*GGA G-AGCA-TG CAGTA*GTG* - * G G * - 1037 wS^ .^S^Q 1^ 33 A^ *CT*TC T*ATGCAATC GCAACAAACG TCG*GGGT** AT*GGA*TTT 1082 
1010 1020 1030 1040 1050 
unMrTirri qRO 1142 TGTCGTGTCG CTGTTTGTGG TGGAGCGAGC AGGCCGGCGG ACCCTGCACC 1 1 9 1 
Z a L U ^ 2 l l Q 1001 C A * T T * T * A C TAC-CAACCA GCATTTTTCA GACGGCTG*T * T * A G C A * A ^ 々。二 HHMSu^3SE0 1205 *TCTC*A*TT --G-G-AAA G**CAG**AG *A*GACT*T* CATA**ATAG 1254 ZoLU^ rSEQ 110S GCSSCC*AT GCCACCA*A* GA*CTG*T*T G*T*AACACA GT*T^CAC*T 1157 
HUMGLU^S'SEQ 1 0 3 8 C*GG*CCGT* A A C G - G - C A - A C C T T C T G C * C * G T * T T C G T G G - G * G * 1 0 8 7 
Z G L u " : i E Q 1083 *TA*TACCAC *AACACA*CT ATA-*A-^ G"TGCA*AA GAT*C*GCTT 1132 
. 1060 1070 1080 1090 1100 
HUMGLUT1 SEQ 1192 TCATAGGCCT CGCTGGCATG GCGGGTTGTG CCATACTCAT GACCATCGCG 1 2 4 1 
H U M G L U ^ 2 i l o 1 0 5 1 CTG*TTATGC AA*CATTGGA * T T - C G C - TA*ACA*GG* T T T - C T - T 1 1 0 0 miMGLU^ l^EO 1255 G-c4-AGG GATG*CTT*T TGTTCCACGC T-*GACTG* TT*TT*GTTA 1304 ZcLU^MlQ 1158 *GG*CTCGG* GTTGTTGG- *A*C*GGCG* GGCGC*GG*C C^T^CATCTC 207 
HUMGLUT5SEQ 1088 **C*G**T*G GAGGCTGC- CT*CTGCTG* G*T*CTC*- CTG*C*-ATA 1137 
S L U ? ? : s l Q 1133 ATG^CACA- G*GCA**GG* AGC*TGAA*T TTC*GACA*C AGTTG*GT*T 1 1 8 2 
1110 1120 1130 1140 1150 
HUMGLUT1 SEQ 1242 CTAGCACTGC TGGAGCAGCT ACCCTGGATG TCCTATCTGA GCATCGTGGC 1291 HUMGLU^2iE0 1101 G*CT*TG*AT *CCTTGT*GA GAAGGCAGG* CGACG*TCTC T*T*TC*AAT 1150 HS^^slc 3^05 ?-L.GGATA ACT*TA*TGG GATGA*CT*T GT**G*A*TG *GGCTA*CTT 1354 HUMGLU^MIo 1208 -G-GC-*G C-GCAT-TG TGG***TGCC AT*CTGA*- CTG*G*CTCT 1257 
HUMGLU^^SEQ ^ 3 8 GCCTGCTGCG -CTCACTGC *G*TCT*GCA CTGC*GGAC* CAG*GTCCTG 1187 
" S ^ ' - S E Q 1 1 8 3 - G A T C G - G * T - * A - G C GGGGC-CG* A - C T G T * C C TGGC**G*AT 1232 
1160 1170 1180 1190 1200 
HlJMGLUTl SEO 1292 CATCTTTGGC TTTGTGGCCT TCTTTGAAGT GGGTCCTGGC CCCATCCCAT 1341 HUMGLU^2'slo 1151 TGGAA*GA*T GGGA-TTTG *T*G-CCA* CTTCATGTCA GTGGGA*TTG 1200 HUMGLU^ailo 13¾ GG*-*TA GCCT*CTTTG AAA-*G*CC A-C-CATT -*TGGTTTA 1404 
n S ^ M l Q 1258 GC-C*GCTG GAGCGA*TTC CAGCCATGAG CTACGTCTC* ATTG*GG*= 1307 
m J M G L U ^ s ' s i o 1 1 8 8 G - G C C A T A * A*CAGCAT*G - * G - T C A * CTCCTAC*T* ATAGGA*ATG 1 2 3 7 ZGLU??:ilQ 1233 G-TGGCATG ***T*CTGTG C*G*CTTCA* *TCG*TG*TA *TGG*GTTGC 1282 
1210 1220 1230 1240 1250 | 
HUMGLUT1 SEQ 1342 GGTTCATCGT GGCTGAACTC TTCAGCCAGG GTCCACGTCC AGCTGCCATT 1391 I HS^2iEQ 1201 T*C*GC*GAA TAAGTTCTCT *GG*TGAGTT A*GTGA*CAT GATA-*：：^  1250 I SLU^ l^EQ 1405 TTG-GGC-A ACTCTTCAG* CAGG-*CCC *C***GC*G* GATG-AG*G 1454 
HUMrni^^qEO 1308 TC**TGG*T* C*TG*C*T*T **TGAGATT* *C**TG*C** CAT*C*TTGG 1357 ‘ ^GLU^^ slo 1238 CCC-GLCC CAG*CCCA*A CC*GCG*T*C TCATCAC*GA GATCTT*C*G 287 
. S L U ? ? : i l Q 1283 T^GAT^AGT* CA*CTGGA*G AGTTATGT*A *CATGACGG^ CATCTT*C"*^ C 1332 
1260 1270 1280 129� 1300 
HUMGLUT1 SEQ 1392 GCCGTTGCAG GCTTCTCCAA CTGGACCTCA AATTTCATTG TGGGCATGTG 1441 
HUMOUT2SE0 1251 TT*C*CTTT* T*AG**T*TT TGAA*TTGGG CCAGG*CCGA -CCC-TG**T 1300 , 
iEi ； 二 二 二 : 二 = : 二 二 ： ！ 
S E ; i 二 二 ? = 二 二 二 二 ; : 二 - -
1 3 1 0 1 3 2 0 1 3 3 0 1 3 4 0 1 3 5 0 
H1MGLUT1 SEQ 1 4 4 2 CTTCCAGTAT GTGGAGCAAC TGTGTGGTCC CTACGTCTTC ATCATCTTCA 1 4 9 1 
E S i ifo^ 5 : 二 : 二 = = 二 二 二 二 5 
H = : | - — 二 = 二 = 二二 = = . -




1360 1370 1380 1390 1400 
HUMGLUTl SEO 1492 CTGTGCTCCT GGTTCTGTTC TTCATCTTCA CCTACTTCAA AGTTCCTGAG 1541 SS?2lEQ llll Ti^*CTGCAT* CAGCAAT*GG AC*TG*AATT T*ATTG*AGC TC*GTG*TTC 1400 
m M r n i ^ V s E O 1555 TCC*CA*TAC CT*CT**GCT * � C * * * * T T*A*AG**CC T*AGA*CCGT 1604 二二二器 ^ 458 ^CCA*TATG* T*CGGA*GCT A*GGGGCC*T A * G T - C T TC*ATT**C* 1507 
^GLU^S'SEQ 1388 GcS*TA*AG CT-CA*TG- ***GC*G*G* T-G-C-CT CACCA*CATC 1 3 7 wS^'-SEQ i4L -AC*T*GGA CTGGG*TCC* AMT*TAAA* AGGG*A*TTG TT*C*AGTCC 1482 
1410 1420 1430 1440 1450 
H,,MGTlITl SEO 1542 ACTAAAGGCC GGACCTTCGA TGAGATCGCT TCCGGCTTCC GGCAGGGGGG 1591 
n S ^ a l l o lVoi C^T^ATTG C - G A — T G -GACCTTA* G T G T T T — TCTTT*CT** 1450 
Z c L U ^ a l l Q 1605 GGC*GGACTT TTGAGGATAT CACACGG-C *TT*AAGGG* A^GCACAC- 1654 
~ T r . s l Q 1508 GTCCTCCTG* T * G G - - T T C ^ C T - A * C * T * ^ G A G T A * C T ^ C 55 
UITM<-TIITR orn 1 d^ fl TAC*TCTT*T T**TTG**CC G****C*AAG G**AAGACGT TCATAAAi iqe, 
S ^ ^ i ^ Q 14^3 I f A c l c ^ l l ? C * _ G * C C ^T*TCATTTC *GG*CG*** * ACGG**T**T 1532 
1460 1470 1480 1490 1500 
HUMGLUTl SEQ 1592 AGCCAGCCAA AGTGATAAGA CACCCGAGGA GCTGTTCCAT CCCCTGGGGG 1641 HUMr^ U^^2SE0 1451 **TGCT**TG GCCTT**CCC TGTT*ACATT TT*TAAAGT* -AGAAACCA 1500 
HUMGLU^^slo 1655 T-AGATAG* TC-GA*-G ACGG-TCAT *GA*A*GA*C AG*A*C*A^C 1704 
HUMGLU^MIo ^558 TCGAG-*GG *CGTT*G*CC AGAT*TCA*C T G C C - * C *GGACACCCT 1607 
HUMGLUT4.SEQ 1 ^ 二二二二 TTCACC**** TGAATA***T *TCTGAAGTG TA**C**AAA 1537 
~ T ? : S E ^ i 5 3 3 J ^ ; ^ G m S * G M ^ T T S T T A * * G ^ T C C A G * A A * ^ A A A ^ ^ A A 1 5 8 2 
1510 1520 1530 1540 1550 
HUMGLUTl SEQ 1642 CTGATTCCCA AGTGTGAGTC GCCCCAGATC ACCAGCCCGG CCTGCTCCCA 1691 HUMSU?2SEQ ir01 AA*GAAAGTC TT-TGAG-AA ATTG*T*CAG -ATTC*AAAA GAA*AGTGGC 1550 
H S ^ ^ l ^ Q i ? 0 5 - - C ^ G G * GACCACCAC* AATGTCT*AG T - G T - * T C C TTCCAC*T*C 1754 
HUMGLU^MIo 1608 -CT-TAG* GCA*GAG-G AAA-CAGCA CAG*A*TT*A GTATT*AGGG 1657 
. m i M ^ ^ S E O 1538 AG-GGAA*T GAAAGAGC*T C*A-T*TCA CTTC*GAACA GTGA*-TGG 1587 二=?:,誌 15^3 A G T C - ™ * C*AAATT*CT **AGA*TTC* GTA-AAGCA *GG*GGTAG* 1632 
1560 1570 1580 1590 1600 
HUMGLUTl SEQ 1692 GCAGCCCTAA GGATCTCTCA GGAGCACAGG CAGCTGGATG AGACTTCC^ 11J1 SLU^2'slo 1551 T-—AC* -CCAAAAGC T*CTGTAGAA AT*AAATTCC TAGGAG*T*C 1600 
HUMrni^lsEO 1755 CTCC-GGC-T -GAAAGC- CCTCTC*CTC A*CAA-GA* --*C-ATC 1804 
Z G L U ^ M g 1 6 5 8 C - * A ? G A G * A C G A - G A G G - C C A G G C A ^ G G * T G * * * G A GCCAGCT*TC 1 7 0 7 
: S = . ! I ^ 1 二 AG-GAAGCC A*TGGAGCTG *TCTGC— GGCT*CCCAC TTTGGCTT*T 1637 nS^7.siQ 1633 C*TC-AAGC TC*GG*GGAT TACAGCG*AT TTCA*AATC* CT*GCGA*C* 1682 
1610 1620 1630 1640 1650 
„,,„^TiiT1 qPO 1742 ACCTGACAGA TGTCAGCCGA GCCGGGCCTG GGGCTCCTTT CTCCAGCCAG 1791 
二=2.1^ 1 6 0 ? 溫 = 2 背脚 A-CT-T-T TT*ACATGAA ^AGA*A^A*T 1650 nS^^ilQ 1805 4GATGA*CC CAGG*CG*TT CTGAATG-* CTA-TAA- *CTTTCT-T 1854 H S ^ M c 1708 T*TACC*G*C CCAG-A*CC CTTCCTTTCC TCTGCAGCAC T*TA*C-TC 1757 
HUMGLUT5SEQ 1638 TTT*CTG*CT *C-AGCTGTC TGT*AATA*C CA*AAATAAA ACAACT*TGA 1687 
^ G L U ^ ^ ^ E Q iell LlGA*G*AG ATGA*AAACG A*T*ACTGAA TTTT*GACG* *ATT*TTT*T 1732 , 
I 
1660 1670 1680 1690 1700 | 
HUMGLUTl SEQ 1792 CAATGATGTC CAGAAGAATA TTCAGGACTT AACGGCTCCA GGATTTT^C 1841 丨 
H U M G L U ^ 2 i E Q 1 6 5 1 A * G G - A C C G T C T G T T T T - A A T G A T G A - CCTT*AG*AT T T T A - A - C C A 1 7 0 0 
H U n S u ^ ^ l E Q 1 8 ¾ *CCACGCACT *CATGAGCAC C C - A * G - G CGGTTTGTTG * A T C - C - T 1904 SLU^Mlo 1758 TCT*CCCTAT T*TTTCCGGG -GG*AA*GAA TC*CTGCAGC CTGG-AG-T 1807 
wnMrni^tilo 1688 TGTG**ATG* AGTCCTC**C *C***CCTCC CCACC*CAGT -GAAC*GTG 1737 ； 
Z o S ^ s l Q 1733 ^ ? T T = * GT^CCCT*G^ GGGCCT*T*A TTTAATAAA^ AA**CCAT*T 1782 | 
1710 1720 1730 1740 1750 | 
HUMGLUTl SEQ 1842 AAAAGCAAGA CTGTTGCTCA AATCTATTCA GACAAGCAAC AGGTTTTATA 1891 
^ ^ i ' n T 9 i p n i i m r ^ T T T * A G TAT*GTT*T* TT*T***GTG CT*TCATC*G *AA^G^C**C 1750 , 
Z r n j ? ^ l l § llol ^CT^^^TA? A * ? - I ? 4 c CTGGACA-C TCTTCTGCTT � A G A G * C C 1954 
. ™ ^ f . s l Q 08 ? G S ™ G GG^ GAAGGGT GG^-GAG- CC*CCT^TT CCCC*CGTGT 
HUMGLUT5 SEQ 1738 C****GGCTG *CT*GCTGTT CT-GA*GCTG *G*TGT*TCT CTCCA*GT-G 1787 ZGLU ?^:llQ 1783 G-CCT^ TT* **CCCAAA*T -AT^TGCAC CT*G*TGCG* *TC*GGC**G 1832 
1760 1770 1780 1790 1800 
m i M r n m SEO 1892 ATTTTTTTAT TACTGATTTT GTTATTTTTA TATCAGCCTG AGTCTCCTGT 1941 =11 issHiH;;s=iiE!- ii EE;i S�i:Si??b======= 二 
# Matched bases are denoted by * 
53 
Results 
i R i n 1820 1830 1840 1850 
HUMOLUTl.SEQ 1942 0 ^ C C ^ ™ C C C T ™ - C . T O C C T O A ^ O A 1J91 
. HUMGLUT2.SEQ 1801 *TAAGAC*GT A*TT^GT*A A * C A * ^ G ^ TAG^TTA , 2054 
HUMGLUT3.SEQ 2005 A-TTTGCCAG *TTTTCCTC* ; T * G G T C ^ A T T G � � * � � 1957 
HUMGLUT4 SEQ 1908 ：器二二丁 ：盖二二* ?二:》芸2 GG^TCCA*CT T — G “ T C * 1887 
" " ' - . s l Q i I e 3 7 . l J ^ ^ " TG^TC^GGA ^^^TTG^TAA ATATATTTG* *ATCGATGTT 1932 
� 1860 1870 1880 1890 1900 
_ _ 测 1 二 二 二 二 二 二 二 二 二 二 ?-
= ¾ ^^ ¾ ? ^ 2 £ ^ s ^ s : s ?：；?；；：：; ^；;^ ^^  二； 
HUMGLUT4.SEQ 1958 T*CCC*AGAC **AGCT*CAG ^ ^ ^ J ^ c A A CAA***T**C *A*AGT**TG 1937 
~ ? ： 1 1 ^ 1S33 二 = : 5 ! G G f c = ^ ： 二 ^ * A * C G G 職 航 肥 1 9 8 2 
1<nO 1920 1930 1940 1950 
HUMGLUTl.SEQ 2042 TGOACCTATO TCCT^GGAC ACACT^TCG ^ C T A T G ^ C T A C ^ G C T T 2091 
HUMGLUT2.SEQ 1901 CTTCTAA*AT * G ^ G - A T T T ^ ^ TATC ^TT T TT 义 2154 
HUMGLUT3.SEQ 2105 G ^ G * A G - A CATATGA*TG TGG^GCCG GGGTGTT^^ cCAG*GCAGA 2057 
HUMGLUT4 SEQ 2 0 0 S *T*GAGGG^ ^；^??^?^^ ^Ga'AG^GAA ^CTA*CTCGG *GGCCCCAAC 1987 
Z S ^ l ' : l l l llll ATTlo^C^C Z ' C G A C G T CTCTA*GAAA TCTA**A"* GTG*GCATA* 2032 
1960 1970 1980 1990 2000 
HUMOLUTl.SEQ 2。92讀。二，0二二。芸=二》=1温器溫二溫溫?- 2141 
HUMGLUT2.SEQ 1951 GA^A^^TGA* GATGC^C*A ATATTTA^A 二 看 ？ -AG^T*TAT 2204 = ^ : - ^ - - ^  i i i H -；-- ^:s^? ; s ^ ; for. 二 二 12二二。。。。;=二=二，—“—？ 2082 
7Cno 2020 2030 2040 2050 
• _ 二 21二 二二 二二 二 ； 二二 二二 ^lo 
=二二 ,^^ 05 二 二 二 二 …一 TTTTT"TT T*ACT*_ 2254 
EE;i Si:iiESi?i!^ S3 t^S$t •= 
oo60 2070 2080 2090 2100 
HUMGLUTl.SBQ 2192 ACCCA.CCAC T = = ™ T T A C J T ^ ^ 》 ， ^ “ ^ flOO 
= ^ : 1 1 ^ � � � �; T - T ^ . ； ™ - ^ ？ ^ ^ ^ T ? ^ - - - - ™ - ^,fo^ 
S ^ 5 - . f E Q 208^8 : A i G : i i v i i : AG^GC^GA GGAA^AGGTT *CTGTGGAGA 讀 … 而 2137 
HUMG^TT.SEQ 2133 TAA*TGGTCA *GCTTAA-A AAAATAAA*A 2182 
2110 2120 2130 2140 2150 
― 二 二 =二二二二 ? 5浩二二二二 --
ZS^ll:lll fs05 :irCA*^ AT* ™ T m T^TTTTTAAO ^TT^^ **AAA^ AA^  望^; 
ZGLU^T5lfEQ 2138 GAA^iiTT^A T^^AA^TTAT TTTGTTAGTG : : ; • ？^二”？了。？ 2187 
HUMGLUT7.SEQ 2183 
2160 2170 2180 2190 2200 
ESSSSEEiiSHiiESE53H b 
二 二 二 g , : : G i : A A : A A & : : : A i i ^ ; i A i ; : T : : : : : : : : : : . . • • : : : : : : ••； 
HUMGLUT7.SEQ 2233 
o p i o 2220 2230 2240 2250 
• HUMGLUTl.SEQ 2342 OOAGCCTOCA ^CTCACTOC - - C ~ C T C 二 = ^^^l 
= ^ : 1 | ^ 二 ^ = " ? 5 = ； 0 G ^ = T T ; ~ - - ： - ^ -
HUMGLUT4.SEQ 2308 2287 
HUMGLUT5.SEQ 2238 2332 
HUMGLUT7.SEQ 2283 
# Matched b a s e s are d e n o t e d by * 
54 
Results 
2260 2270 2280 2290 2300 
HUMGLUT1. SEQ 2392 GTGTATAGAT GCAAGATATT TATATATATT TTTGGTTGTC AATATTAAAT 2441 
HUMGLUT2.SEQ 2251 AAAG*A*ACC ATTTT*GT*C CT*TAT*TAA *GGCCAAA*G GT*T**GC*A 2300 
HUMGLUT3.SEQ 2455 AGAA**GTTG TTC*TTAT*G G*GGGTA*A* GA**TGGTG* CTG*GGTCTG 2504 
HUMGLUT4.SEQ 2358 2407 
HUMGLUT5. SEQ 2288 2337 
HUMGLUT7. SEQ 2333 2382 
• 
2310 2320 2330 2340 2350 
HUMGLUT1. SEQ 2442 ACAGACACTA AGTTATAGTA TATCTGGACA AGCCAACTTG TAAATACACC 2491 
HUMGLUT2.SEQ 2301 GATTTA**AC TAAA*AG**T *CA*CT**TC *TAT*G*G** GGTTAT**GT 2350 
HUMGLUT3.SEQ 2505 TAC*TT**CT CT*A*C*A*T *C*G*CCTTC **ATGGAAAC *CTT**ACTT 2554 
HUMGLUT4.SEQ 2408 2457 
HUMGLUT5.SEQ 2338 2387 
HUMGLUT7. SEQ 2383 2432 
2360 2370 2380 2390 2400 
HUMGLUTl.SEQ 2492 ACCTCACTCC TGTTACTTAC CTAAACAGAT ATAAATGGCT GGTTTTTAGA 2541 
HUMGLUT2. SEQ 2351 TAACATTAA* ATC**T*ATA AA*CCAT*T* GATTCCCTTC T*G*ACA*TC 2400 
HUMGLUT3.SEQ 2555 CT*GT*AAAG *CA**TACCT A**T*ATA*A GCT*C**AT* TCC**GG**C 2604 
HUMGLUT4.SEQ 2458 2507 
HUMGLUT5.SEQ 2388 2437 
HUMGLUT7. SEQ 2433 2482 
2410 2420 2430 2440 2450 
HUMGLUTl.SEQ 2542 AACATGGTTT TGAAATGCTT GTGGATTGAG GGTAGGAGGT TTGGATGGGA 2591 
HUMGLUT2.SEQ 2401 CTTTGA***A *AGTT***** TGCTT**T*A TTG****CAG CCT*G*TTTC 2450 
HUMGLUT3. SEQ 2605 TTTT*TC*** AAG*TAATAG T*TACA**TA *TAGTACTTG AAATC*A*** 2654 
HUMGLUT4.SEQ 2508 2557 
HUMGLUT5.SEQ 2438 2487 
HUMGLUT7. SEQ 2483 2532 
2460 2470 2480 2490 2500 
HUMGLUTl.SEQ 2592 GTGAGACAGA AGTAAGTGGG GTTGCAACCA CTGCAACGGC TTAGACTTCG 2641 
HUMGLUT2. SEQ 2451 ACATACACTC *AAC*A*CAT *AGT**GA** T*TGGTATAT *ACCT*AAAT 2500 
HUMGLUT3.SEQ 2655 T*ATT*ACT* *TATG*GCAT TG*AGTTAAT GATGGTT*AT GGGTT**AAT 2704 
HUMGLUT4.SEQ 2558 2607 
HUMGLUT5.SEQ 2488 2537 
• HUMGLUT7. SEQ 2533 2582 
2510 2520 2530 2540 2550 
HUMGLUTl.SEQ 2642 ACTCAGGATC CAGTCCCTTA CACGTACCTC TCATCAGTGT CCTCTTGCTC 2691 
HUMGLUT2. SEQ 2501 T*CT*AT*AG TTTGAT*AA* TCTAATGTAA GA*AATT**A AG*AAA*GAT 2550 
HUMGLUT3.SEQ 2705 TT*GGATGGA GTCCAGGGA* G*GAA*GTGA *TTCT**AAA G*CTG*T*C* 2754 
HUMGLUT4.SEQ 2608 2657 
HUMGLUT5. SEQ 2538 2587 
HUMGLUT7. SEQ 2583 2632 
2560 2570 2580 2590 2600 
HUMGLUTl.SEQ 2692 AAAAATCTGT TTGATCCCTG TTACCCAGAG AATATATACA TTCTTTATCT 2741 
HUMGLUT2.SEQ 2551 TG*TCA**T* G*T*AAAA*A **TT*TGA*T T**TATGT*T CAAAA**AG* 2600 
HUMGLUT3.SEQ 2755 CTC*C*GGA* GAA**AA**C C*T*TTGT** T*GTCTC*TT ACT***GAAG 2804 
HUMGLUT4.SEQ 2658 2707 
HUMGLUT5.SEQ 2588 2637 
HUMGLUT7. SEQ 2633 2682 
2610 2620 2630 2640 2650 
HUMGLUTl.SEQ 2742 TGACATTCAA GGCATTTCTA TCACATATTT GATAGTTGGT GTTCAAAAAA 2791 
HUMGLUT2.SEQ 2601 ***A*AGGT* **GT**GAGG ATT*C*GAG* *TGG*C*TC* *AAACTTC*T 2650 
HUMGLUT3.SEQ 2805 *A*TCCCGCC AC*TA*CTCG *GGG*G*GCC ATCCAAATAA *AAACCT*** 2854 
HUMGLUT4.SEQ 2708 2757 
HUMGLUT5.SEQ 2638 2687 
HUMGLUT7. SEQ 2683 2732 
2660 2670 2680 2690 2700 
HUMGLUTl.SEQ 2792 ACACTAGTTT TGTGCCAGCC GTGATGCTCA GGCTTGAAAT CGCATTATTT 2841 
HUMGLUT2.SEQ 2651 *A*TGTTCAG CT*CAG*CTT T*ATCAAAAT CC**ATTT*A TTTTCCTGGA 2700 
HUMGLUT3.SEQ 2855 *T*A*T*G** CT**GT**AG A*TCATTATT TTTCCACTT* GTTC**TAGG 2904 
HUMGLUT4.SEQ 2758 2807 
• HUMGLUT5.SEQ 2688 27 37 
HUMGLUT7. SEQ 2733 2782 
# Matched bases are denoted by * 
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2710 2720 2730 2740 2750 
HUMGLUTl.SEQ 2842 TGAATGTGAA GGGAA 2891 
HUMGLUT2.SEQ 2701 AAG*CTGATT *TTTTATGGT GTGTTCCTAA CATAAAATAA TCGTCTCCTT 2750 
HUMGLUT3.SEQ 2905 A**T*T*AGG T*TTGATTTT CTGTTGTATT TTAACTCATA CCTTTAAAGG 2954 
HUMGLUT4.SEQ 2808 2857 
HUMGLUT5.SEQ 2738 27 87 
HUMGLUT7. SEQ 2783 2832 
# Matched b a s e s a r e d e n o t e d b y * 
Fig. 3.2 Alignment of cDNA sequence of different human 
glucose transporter isoforms. 
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3.3 P^Pl-labeled oligonucleotide uptake assav 
In order to determine whether the oligonucleotides could be 
taken up by HL-60 cell, oligonucleotide uptake assays were 
performed • Radioactivity retained by the washed cell pellets was 
compared with that left in the culture medium and the wash. The 
percentage of oligonucleotide uptake was calculated as follows: 
% oligonucleotide uptake = cpm (cell pellet) x 100% 
cpm (cell pellet, wash and medium) 
About 3-4% of the labeled oligomers were found associated 
with the cell pellet after 10 hours, a proportion that remained about 
the same up to 30 hours. The percentage oligonucleotide uptake of 
15-mer and 30-mer oligonucleotides were compared to see how 
oligonucleotide length affected the uptake efficiency (Fig. 3.3). 
Another set of experiment using the Lipofectin Reagent 
resulted in improvement of oligonucleotide uptake (Fig. 3.4) 
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Fig. 3.3 The percentage oligonucleotide uptake of antisense 
oligonucleotides with different lengths in HL-60 cells. 
The mean and standard deviation were shown on the graph. 
Each experiment was repeated in triplicate. 
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Fig. 3.4 The percentage oligonucleotide uptake of antisense 
oligonucleotide encapsulated into liposome in HL-60 cells. 
The mean and standard deviation were showed on the graph. 
Each experiment was repeated in triplicate. 
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3.4 Antisense oligonucleotides designed against different 
regions of GLUT1 cDNA seauence 
3.4.1 Effects on HL-60 cell proliferation 
MTT assay was used to quantify the viable cells and hence the 
percentage of cell proliferation. This method was more precise than 
the cell counting by Trypan blue exclusion method. The active 
enzyme in viable cells would reduce MTT and the color would be 
changed after reaction. The changes in color will then be detected by 
absorbance measurement. In each set of experiment, a negative, 
sense and scramble control were included. The percentage 
proliferation of negative control was assigned to be 100%. All the 
other datas were calculated by the following formula: 
% Cell Proliferation = Absorbance (sample) x 100% 
Absorbance (control) 
In order to determine the optimal incubation time, a time-
course assay was performed. The percentage cell proliferation was 
checked after incubating with the antisense oligonucleotides for 8， 
12，16，20，24, 30，36 and 48 hours (Fig. 3.5). 
The positional effect of antisense oligonucleotide was tested by 
designing oligonucleotides at different region, including 5， 
untranslated region (141)，start codon (169), coding region (750) and 
3，untranslated region (1592). The result was shown in Fig. 3.6. 
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Fig. 3.5 The effect on HL~60 cell proliferation by incubating with the 
oligonucleotides (AS169-S) for different time intervals. 
The mean and standard deviation were shown on the graph. Each 
experimentwas repeated in triplicate. 
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I I Control 
^ Sense 
^ Antisense 
^ M Scramble 
120 ^  
100 - 1 '^ "" |Xj ^ p^ __ 
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141 169 750 1592 
Fig. 3.6 The effect on HL~60 cell proliferation by sense,antisense 
and scramble-sequenced oligonucleotides designed at position 14 
1,169，750,1592 within GLUT1 cDNA sequence. All negative 
control was set at 100% cell proliferation. 
Position 141-at 5' untranslated region; 169-next to start codon 
(ATG); 750- within coding region; 1592- at 3' untranslated region. 
The mean and standard deviation were shown on the figure. 




3.4.2 Effects on GLUT 1 mRNA level 
The full-length GLUT 1 cDNA was prepared by PCR using a 
pair ofprimers (Gl-F: 5，ATGGAGCCCAGCAGCAAGAAGCTGAC 
G 3，； G2-R: 5，TCACACTTGGGAATCAGCCCCCAGGGG 3，) (Fig. 
3.7). Full length GLUT 1 cDNA (1.5 kb) was used to probe for GLUT 
1 mRNA (2.8 kb). 
Results of Northern hybridization showed that the GLUT 1 
mRNA was lowered when the antisense oligonucleotide was directed 
to the initiation codon (AS169) when compared with the controls 
(Fig. 3.8). Normalization was made by equalizing the quantity of 18S 





I — 1.5kb 
Fig. 3.7 Gel electrophoresis by 1% TBE agarose gel showing 
GLUT 1 PCR product (1.5 kb) which was used as probe in 
performing Northern hybridization. Lane M: \ Hind III DNA 
marker; Lane 1: GLUT 1 PCR product. 
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Fig. 3.8 Northern analysis of GLUT 1 mRNA expression in 
HL-60 cells. Lane 1: negative control without treatment; Lane 
2: sense control; Lane 3: antisense oligonucleotide treatment; 




Fig. 3.9 Normalization of total RNA prepared from HL-60 
cells using gel electrophoresis in 1% TAE agarose gel. Lane 1: 
negative control without treatment; Lane 2: sense control; 




3.5 The effects of different oligonucleotide concentrations 
on HL-60 cell proliferation 
Oligonucleotides of high concentration might produce toxicity 
to the cells, so oligonucleotide concentration must be optimized to 
produce maximum antisense effect and minimum toxicity. A range of 
oligonucleotide concentration (5-25 i^M) was tested (Fig. 3.10). It was 
found that similar antisense effect was resulted at concentration 10-
25 i^M. To prevent toxicity due to high oligonucleotide concentration, 
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Fig. 3.10 The effect of different oligonucleotide concentration on 
HL"60 cell proliferation. 
The mean and standard deviation were shown on the figure. Each 
experiment was repeated in triplicate. 
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3.6 The effects of modified oligonucleotides on HL-60 cell 
proliferation 
It was assumed that if the phosphorothioated oligonucleotide 
was more resistant to nuclease attack, higher inhibition of cell 
proliferation should be resulted for the same concentration as the 
unmodified oligomers. 
10 i^M of modified and unmodified antisense oligonucleotides 
(AS169, 15-mer) were added to HL-60 cells and the percentage of cell 
proliferation was measured by MTT assay. The result showed that 
higher inhibition was resulted with phosphorothioated 
oligonucleotide (Fig. 3.11). 
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Fig. 3.11 The effect on HL^O cell proliferation by phosphorothioated 
oligonucleotides (S-oligomer). 
The mean and standard deviation was shown on the figure. Each 
experiment was repeated in triplicate. 
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3.7 The effects of different oligonucleotide lengths on 
HL-60 cell proliferation 
Oligonucleotide length exerted great effect on uptake efficiency 
of oligonucleotides by cells. It also determined the binding specificity 
to target nucleic acid. Antisense oligonucleotides with length 15-mer 
and 30-mer at position 169 were designed together with the sense 
and scramble control. Measurement of percentage cell proliferation 
was performed by MTT assay and the result was shown in Fig. 3.12. 
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Fig. 3.12 Effects on percentage cell proliferation by antisense 
oligonucleotide ofdifferent lengths. 
The mean and standard deviation were shown on the figure. Each 
experiment was repeated in triplicate. 
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3.8 PHl-deoxvglucose uptake assav 
GLUT 1 protein was mainly located at the cell membrane. To 
detect the quantity of GLUT 1 protein, we could measure the glucose 
uptake rate by the cells. In order to prevent degradation of glucose 
after transporting into the cells, deoxyglucose was used. To calculate 
the glucose uptake rate, the following formula was used: 
Glucose Uptake Rate = cpm (sample) x 1 pmol  
cpm (control) x 1x10® cell x time (min) 
* Control: 1.9 i^l or 1 pmol of [^H]-deoxyglucose solution stock was 
added to the cells without any antisense treatment 
In order to ensure deoxyglucose was uptaken by cells at 
constant rate, a time-course assay was performed to find out the 
linear region for constant glucose uptake rate (Fig. 3.13). The results 
showed that 5-12 minutes was optimal for glucose uptake assay and 
in other glucose uptake assays, the cells were incubated for 7 
minutes after addition of PH]-deoxyglucose. 
Antisense oligonucleotide (AS169) of 10 ^M was incubated 
with HL-60 cells. Glucose uptake assay was performed after 
incubation. In Fig. 3.14, it could be seen that the GLUT 1 protein 
level decreased about 40% when treated by antisense 
oligonucleotides while sense and scramble oligonucleotide just 
showed slight difference with the negative control. 
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Fig. 3.13 The effect on [^H]-deoxyglucose uptake by HL-60 cells at 
different incubation period. 
The mean and standard deviation were shown on the graph. 
Each experiment was repeated in triplicate. 
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Fig. 3.14 The effect on fH]<leoxyglucose uptake rate of HL*60 
cells treated by sense, antisense and scramble oligonucleotides. 
Control - negative control without any treatment. 
The mean and standard deviation were shown on the figure. Each 
experiment was repeated in triplicate. 
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3.9 Cloning of sense and antisense GLUT 1 cDNA into 
pRc/CMV vector 
The plasmid stock containing GLUT 1 full-length cDNA (2.5 
kb) was amplified by large scale plasmid preparation (Fig. 3.15). The 
insert was cloned into the vector pGEM3 with cloning site BamHL In 
order to clone into the vector pRc/CMV (Fig. 3.16) to express sense 
and antisense nucleotides, PCR was performed with two pairs of 
primers (pRc-SF and pRc-SR; pRc-ASF and pRc-ASR) containing 
cloning sites ofi/md//Jand Not L Two PCR products, one with sense 
strand and the other one with antisense strand of size 1.5 kb, were 
obtained (Fig. 3.17). After restriction digestion (Fig. 3.18) and 
ligation, GLUT 1 plasmid containing insert with sense and antisense 
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Fig. 3.15 Preparation of plasmid containing GLUT 1 cDNA. 
Lane M: X Hind III DNA marker; Lane 1: plasmid containing 
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Fig. 3.16 Preparation of pRc/CMV plasmid vector. Lane M: X 
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Fig. 3.17 Agarose gel electrophoresis of GLUT1 PCR 
products containing the whole coding region. Lane M: X Hind 
III DNA marker; Lane 1 GLUT 1 cDNA at sense orientation; 
Lane 2: GLUT 1 cDNA at antisense orientation. 
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Fig. 3.18 Restriction digest product of plasmid vector 
pRc/CMV and GLUT 1 cDNA insert clone. DNA was digested 
with Hind III and Not I and then fractionated by 1% TBE 
agarose gel. Lane M: X Hind III DNA marker; Lane 1: plasmid 
vector pRc/CMV; Lane 2: GLUT 1 cDNA insert at sense 
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Fig. 3.19 Plasmids prepared after transformed into JM109 
bacterial cells. Lane M: 1 Hind III DNA marker; Lane 1: 
Plasmid containing sense cDNA strand; Lane 2: plasmid 
containing antisense cDNA strand. 
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3.10 Inhibition of GLUT1 gene expression bv expressed 
antisense nucleotides 
After cloning the GLUT 1 insert into pRc/CMV, the plasmid 
was transfected into HL-60 cells by liposomes. The DNA to liposome 
ratio was optimized to be 1:5 (Fig. 3.20). MTT assay was used to 
measure the percentage of cell proliferation. By the time-course 
assay, the antisense effect was greatest (i.e. lowest percentage cell 
proliferation) for 72 hours-incubation time (Fig. 3.21). Plasmid vector 
expressed nucleotide produced more than 50% inhibition of cell 
proliferation (Fig. 3.22). The plasmid vector control without insert 
clone and the sense control produced slight difference in cell 
proliferation when compared with the negative control. The result of 
Northern hybridization also showed that a drastic decrease in mRNA 
expression was detected after treatment by expressed antisense 
nucleotide (Fig. 3.23 and Fig. 3.24). Glucose uptake assay confirmed 
a great decrease in GLUT 1 protein expression by treating with 
expressed antisense nucleic acid (Fig. 3.25). 
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Fig. 3.20 The effect on HL-60 cell proliferation by different DNA to 
liposome ratio. 1 ^g of DNA was used in each set of experiment. 
The mean and standard deviation were shown on the figure. Each 
experiment was repeated in triplicate. 
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Fig. 3.21 The effect on HL-60 cell proliferation by treatment with 
expressed sense and antisense nucleotides for different time 
intervals. 
The mean and standard deviation were shown on the graph. Each 
experiment was repeated in triplicate. 
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Fig. 3.22 The effect of expressed sense and antisense nucleotides 
on HL-60 cell proliferation. Control - negative control without any 
treatment; Vector - only the vector pRc/CMV was used as control. 
No insert was cloned into the vector. 
The mean and standard deviation were shown on the figure. Each 
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Fig. 3.23 Northern analysis of GLUT 1 mRNA expression in 
HL-60 cells. Lane 1: negative control without treatment; Lane 
2: sense control; Lane 3: antisense treatment; Lane 4: plasmid 
vector control without insert. 
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Fig. 3.24 Normalization of total RNA prepared from HL-60 
cells using gel electrophoresis in 1% TAE agarose gel. Lane 1: 
negative control without treatment; Lane 2: sense control; 
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Fig. 3.25 The effect on fH]-deoxyglucose uptake rate of HL-60 
cells treated with expressed sense and antisense nucleotides. 
Control - no treatment; Vector -vector without any insert clone. 
The mean and standard deviation were shown on the figure. Each 








4.1 Importance of GLUT 1 gene 
The diversity of glucose transporters expressed in mammalian 
tissues reflects the importance of glucose as a source of metabolic 
energy, and different glucose transporters are evolved to allow its 
dietary uptake and tissue-specific utilization. The presence of GLUT 
1 mRNA in almost all human tissues suggests that this isoform 
might mediate basal glucose uptake. The biochemical properties of 
this protein seem well suited for this role. The GLUT 1 protein has a 
Km for glucose of � l m M . Normal serum glucose concentration is 
maintained between 3.9 and 8.4 mM (Bell, et al., 1990). Thus, 
glucose uptake by the GLUT 1 protein would be near maximal under 
normal physiological conditions. This is an important feature for 
tissues such as brain that utilizes glucose preferentially as a source 
of metabolic energy. 
Significant increases in abundance of mRNA for GLUT 1 in 
cancers of the esophagus, colon, pancreas, and many other human 




4.2 HL-60; the target cancer cell line 
Overexpression of GLUT 1 appear in most of the cancer cell 
lines. One of them, HL-60, is a promyelocytic leukemia cell line. So 
far，the antisense strategies have been applied on this cell lines with 
c-m;yc oncogene as the target gene O^ickstrom, 1992; Kimura et al” 
1995). The antisense oligonucleotides against c-myc gene had been 
successfully inhibited the proliferation of HL-60 cells. Since GLUT 1 
is an important transporter for glucose uptake in HL-60 cells, it is of 
interest to test the probable inhibitory effect of antisense 
oUgonucleotides against GLUT 1 on this gene expression to decrease 
tumor cell proliferation. 
4.3 Importance of“Antisense Approach，， 
So far, several approaches could be used to knock out the 
expression of a gene. One of them, the "Antisense approach，，，was 
widely applied in the past few years. 
In my project, both antisense oligonucleotides and expressed 
antisense nucleotides against GLUT 1 gene sequence were used. For 
antisense oligonucleotides designed at position 169，a transient 
inhibition of HL-60 cell proliferation of about 25-30% could be 
detected by MTT assay. Maximum inhibition appeared at about 24 
hours after the oligonucleotides were uptaken by the cells (i.e. 48 
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hours after addition of oligonucleotide to the cells). Results from 
Northern analysis showed a slight decrease in GLUT 1 mRNA. 
Specificity of this inhibition was demonstrated by the fact that the 
sense oligomer had no effect on cell proliferation and neither did the 
scramble oligonucleotides. The sequence of scramble oligonucleotide 
was sent to the GeneBank and no match with other cDNA sequence 
was found. So, it was preliminary believed not to hybridize to any 
DNA strand within cells and did not produce non-specific antisense 
effects. 
The inhibition of c-myc and c-fec expression by antisense 
oligonucleotides on HL-60 was also reported O^ickstrom, 1992; 
Manfredin et aL, 1997). Treatment of HL-60 cells with 4 [iM anti-c-
myc oligomer reduced cell proliferation by about 55% while 
treatment by anti-c-/es oligonucleotides resulted in a dramatic 
decrease of mRNA abundance that was detected by Northern 
Hybridization. However, when antisense approach with 
oligonucleotide worked against oncogene, the expression of their 
genetic precursors, proto-oncogenes, must be carefully monitored. 
Since there may be only one or a few difference in the base-sequence 
due to mutations between them, it is challenging to differentiate 
between a proto-oncogene and its oncogene product. Therefore, 
medium-length oUgonucleotide was a key to the antisense selectivity. 
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4.4 Optimization of condition for antisense inhibition bv 
oligonucleotides 
To achieve maximum antisense effect, several factors must be 
considered. These included oligonucleotide, oligonucleotide 
modification, sequence selection and uptake efficiency. 
4.4.1 Oligonucleotide length 
Oligonucleotide length would affect the uptake efficiency. 
Generally, the longer the oligonucleotide, the lower would be the 
uptake efficiency. From Fig. 3.3 and Fig. 3.12，15-mer and 30-mer 
oligonucleotide did not show great difference in their uptake 
efficiency and in percentage cell proliferation. One of the possible 
reasons might be that 3-4% of oligonucleotide uptake was the 
optimal result under these condition. So 15-mer oligonucleotide 
would not result in much higher uptake efficiency without changing 
the condition. Besides the uptake efficiency, oligonucleotide of long 
sequence will produce toxicity to the cells. However, from the results, 
30-mer oligonucleotide did not seem to produce toxicity when 




4.4.2 Oligonucleotide Modification 
A prerequisite to the use of antisense oligonucleotides as 
therapeutic agents is the information on the stability of oligomers in 
the biological milieu. In a study, the degradation of 5’ end and 
internally p2p] labeled unmodified oligomer and analogs containing 
phosphorothioate (S-oligo) was studied in HeLa cell nuclear extract, 
S100 cytoplasmic extract, normal serum and calf serum at 37°C 
(Akhtar, et al” 1991). Unmodified oligomers showed complete 
degradation within 30 minutes of incubation in human serum at 
37°C whereas S-oligos exhibited some degradation products after 60 
minutes of incubation. Under the same experimental condition, 
greater degradation of oligomers was observed in calf serum than in 
normal human serum or nuclear extract. Even in heat inactivated 
fetal calf serum (heated to 56°C for one hour), unmodified oligomer 
was found to be degraded at about 10 minutes whereas degradation 
of S-oligo was observed within one hour. These experiments showed 
that oligonucleotides when added to a culture system were rapidly 
degraded in the presence serum in the culture medium. Thus, in my 
study, at the first 24 hours after addition of oligonucleotides, serum-
free medium was used. The medium with 20% serum was added to 
make the final serum concentration to be the normal 10% and the 
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cells were further incubated for the oligonucleotides to take their 
effects. 
Another approach to prevent degradation of oligonucleotides 
by nuclease is to modify the structure of oligonucleotides and make 
them to be more nuclease-resistant. Phosphorothioated 
oligonucleotides are simple to synthesize that only a sulfurization in 
place of the normal oxidation step is required at the last step in the 
cyclic synthesis. They contained a sulfur atom in the phosphodiester 
group in place of one of the nonbridging oxygens, and thus they had 
the same charge as the parent compound. 
Another study (Stein, et al” 1988) compared the 
susceptibilities of a series of normal oligomers and their 
phosphorothioated derivatives toward three different nuclease: Sl 
(predominantly an endonuclease), P1 (endo- and exonuclease), and 
snake venom phosphodiesterase (SVP, a 3，，5，exonuclease). All the S-
oligos were more stable than the normal derivatives toward the 
enzymes tested. The result was very prominent with SVP, where the 
relative half-life of the S-oligos was about lO-2 - 10"^  that of the 
unmodified. With other nucleases, the digestion also proceeds one-
half to one-fifth as fast as the S-oligos. Such results are important 
since stability under biological conditions is one of the critical 
requirements for a prolonged effect of gene inhibitory substances. 
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Serum, blood plasma, and cytoplasm all contained nucleases. Thus, 
nuclease resistance is needed to be addressed for cell culture 
experiments as well as for the use of gene inhibitors in animals or 
humans. 
From the result of my study, phosphorothioated 
oligonucleotides resulted in greater inhibition of cell proliferation 
than the normal oligonucleotides. The difference was about 10%. So, 
a combination of serum-free medium and modified oligonucleotides 
would give a good choice for antisense approach. 
4.4.3 Sequence selection 
The comparison of the efficiency of different antisense 
oligonucleotides directed against different regions of target mRNA is 
another critical issue in my work. 
Several regions within the sequence of the target gene could be 
chosen to design the oligonucleotides. 5，untranslated region, region 
around the start codon, amino acid coding region and 3，untranslated 
region were selected to test the antisense effects. Antisense 
oligonucleotide with sequence around the start codon (AS169) of 
GLUT 1 cDNA resulted in greater inhibition proliferation and the 
Northern analysis also indicated similar results. The sequences 
around the translation initiation codon is the most frequently chosen 
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region for targeting. A recent study reported that the efficiency of 
antisense oligonucleotides targeted against the first splice donor-
acceptor site of human basic fibroblast growth factor gene was 
satisfied (Anazodo, et al.，1995). Another report has suggested that 
the 5'-capping region was another excellent region for targeting by 
antisense oligonucleotides (Barton, et al” 1995). 
However, my results show that antisense oligonucleotides 
targeted against the start codon of GLUT 1 gene did not exert great 
efficiency although this region still resulted in highest inhibition of 
cell proliferation among the four regions chosen. Therefore, it is 
concluded that selection and characterization of high affinity 
antisense oligonucleotides is required when a new specific target 
gene is studied for the first time. 
4.4.4 Uptake efficiency 
Oligomers are now believed to be taken up by highly inefficient 
pinocytosis and/or by receptor-mediated endocytosis after binding to 
cell surface proteins; several candidate receptors have recently been 
described and partially characterized (Yakubov, et al.，1989). In 
addition, most of all intracellular oligomers are sequestered in 
vesicles, still separated from the target mRNA, technique has been 
developed to promote intracytoplasmic delivery of oligonucleotides. 
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From Fig. 3.3, only about 3-4% of oligonucleotide was taken by the 
cells. This result is comparable with other study on the inhibition of 
c-myc gene expression in HL-60 cells. Only about 2% of 
oligonucleotide was uptaken by HL-60 cells when the cells were 
treated with anti-c-mj'c oligonucleotides of 15-mer in length 
OVickstrom, 1992). 
As a general rule, plasma membranes of living cells restrict the 
transportation of large and negatively charged molecules. It might 
therefore be expected that this membrane would also act as a barrier 
for polyanionic molecules such as oligonucleotides. 
To increase oligonucleotide uptake, HL-60 cells were treated 
with the oligonucleotides encapsulated with Lipofectin Reagent. 
Lipofectin reagent alone was also added to cell culture medium to 
determine its cytotoxicity and no more than 3% decrease in cell 
proliferation was obtained. This shows that the quantity of 
Lipofectin Reagent used in the experiment produced no toxicity to 
the ceUs. 
The percentage oligonucleotide uptake increased about 40% 
when oligonucleotides were encapsulated into liposomes before 
uptake. It is important to optimize the amount of oligonucleotide and 
Liposome used. The results of MTT assay showed that for each ^g of 
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DNA, 5 \ig of Lipofectin Reagent was required to produce maximum 
uptake (Fig. 3.20). 
Oligonucleotides can be transported to the nucleus and bound 
to the DNA strand. This is confirmed by the inhibition of 70-kDa 
heat-shock protein transcription and replication of HIV (Anazodo et 
al” 1995) by antisense oligonucleotides targeted to splice sites of 
viral precursor RNA, because these activities take place only in the 
nucleus. 
Besides using liposomes, antisense oligonucleotides can be 
microinjected into the cell nucleus or get entering the cells by 
electroporation. However, microinjection involves more difficult 
technique while electroporation might kill many cells and so the 
initial cell number required is much higher. 
4.5 Intracelluar distribution of oligonucleotides 
The antisense concept was initially based on the assumption 
that oligomers might interact with mRNA to block their translation. 
However, the actual site of action of antisense oligomers has not 
been firmly established in intact cells. Since the targeted sequence is 
not only present in the mRNA but is also in the primary transcript, 
interference with pre-mRNA maturation or nucleocytoplasmic 
transport can also be envisaged. 
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Free, or Uposome-encapsulated oUgomers are internalized 
through an endocytic pathway. Indeed, punctuated cytoplasmic 
labeUng, which is characteristic of accumulation in the endocytic 
vesicles, is observed when fluorescently tagged oligomers are 
incubated with celLs (Loke, et ah, 1989). How oligonucleotides escape 
these vesicles to reach their cellular target remains a matter of 
conjecture. Experiment was performed to ascertain the intracellular 
location of oligomers by microinjecting them into the cytoplasm of 
somatic cells (Leonetti, et al.，1991). A 15-mer oligonucleotide 
conjugated at its 5，end to tetramethylrhodamine isothiocyanate 
accumulated in the nuclei of microinjected REF-52 rat embryo 
fibroblasts. This location was apparently not influenced by the 
technique of cell fixation, by the nature of the fluorochrome, or by the 
release of this molecule. Experiments performed under inverted 
fluorescent microscopy on living cells revealed the swiftness of this 
phenomenon: translocation to the nuclei was nearly complete 1 
minute after microinjection. This process remained unaffected in its 
rate and magnitude upon ATP depletion or low-temperature 
incubation. 
These arguments favor a diffusion process through the nuclear 
pores, compatible with the small size of the oligonucleotides. 
However, the accumulation of nuclear materials implies the 
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existence of nuclear binding sites. Photosensitive oligonucleotides 
incubated with isolated nuclei bind a small number of nuclear 
proteins ranging from 36 to 48 kDa (Leonetti, et al” 1991). This 
observation provides interesting prospects for a better understanding 
of the action mechanisms of antisense oligonucleotides. 
4.6 Inhibition of GLUT 1 gene expression bv expressed 
antisense nucleotides 
In the part of inhibition of gene expression by antisense 
oligonucleotides, only about 30% of inhibition was achieved and the 
effect was transient. In my study, I have used an mammalian 
expression vector, pRc/CMV, to express antisense nucleotides. The 
protocol for cloning was shown in section 2.2.2 and the results were 
shown in Fig. 3.15- Fig. 3.19. After cloning the sense and antisense 
DNA strand into the vector, large scale plasmid preparation was 
performed. Negative control without any treatment and vector 
without any insert clone were used as a control for nonspecific effects 
of transformation or plasmid integration. From the result, over 50% 
of inhibition of cell proliferation was observed as detected by MTT 
assay (Fig. 3.22). By Northern analysis, the expression of GLUT 1 
mRNA was decreased (Fig. 3.23). The glucose uptake rate by HL-60 
cells, depending on the number of GLUT 1 proteins present on cell 
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membrane, was also decreased more than 50% when the cells were 
transformed by plasmid containing antisense GLUT 1 cDNA strand 
(Fig. 3.25). 
When comparing the efficiency between oligonucleotides and 
expressed nucleotides in inhibiting GLUT 1 gene expression, 
expressed nucleotides produced much greater antisense effect. This 
might be due to greater number of antisense strands produced by the 
vector than the oligonucleotides. 
The antisense effect produced by antisense oligonucleotides 
was transient and the effect was resulted within 24 hours after 
oligonucleotides uptake. For expressed nucleotides, the effect was 
taken only after 72 hours. Longer time was required for the vector to 
express the antisense nucleotides. 
In my study, full-length GLUT 1 cDNA was cloned into the 
vector. The expression of GLUT 1 RNA containing the whole coding 
region provided high specificity in binding to the target mRNA when 
compared with the short length of oligonucleotides. Another study on 
inhibition of myosin heavy chain II OMHC II) gene expression by 
antisense RNA showed that the size of the antisense sequence had 
an effect on the extent of inhibition (Scherczinger, et al., 1992). Both 
the 3.7 kb fragment and the 2 kb fragment derived from MHC II 
gene gave complete inhibition of expression. When a 396-bp 
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fragment contained within the 2 kb fragment was tested, no 
inhibition was observed. In addition, the vector containing the entire 
8 kb MHC II sequence gave only partial inhibition. Therefore, the 
size of the antisense sequence, as well as portion of the gene used 
was important. 
4.7 Mechanism for antisense inhibition of gene expression 
At the beginning of "antisense history", oligomers were 
generally designed to interfere with mRNA translation; hence 
molecules were also called "anti-messengers". Oligonucleotides 
complementary to the region between the cap site and the initiator 
AUG codon can block the translation machinery in an RNase-H-
independent mechanism. This has been demonstrated either by 
using mammalian reticulocyte lysates (Helene, et al” 1994) or by 
using oligomer analogs whose hybrids are not processed by RNase H. 
Once the translation machinery has been completely assembled, 
unwinding activities associated with the ribosomes will process the 
hybrids and render antisense oligomers inefficient unless RNase H 
has hydrolyzed the target RNA. 
On intact cells, however, little is known about the actual 
mechanisms of action of antisense oligonucleotides, although a large 
number of genes had been inhibited using this concept. The 
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hybridization of antisense oligonucleotides with the targeted mRNA 
and the mechanism of translation inhibition had generally not been 
formally proved. A direct answer would probably have to await tools 
to analyze the intracellular distribution of RNase H activity. 
Furthermore, if an oligomer can potentially act at the translation 
level, it can also interfere with other stages of mRNA maturation 
such as splicing, nucleo-cytoplasmic transport or metabolic stability. 
From the result of Northern analysis, the mRNA level was 
decreased by both antisense oligonucleotides and expressed 
antisense nucleotides. Also, the process of translation was inhibited 
as detected by glucose uptake assay which indicated the number of 
GLUT 1 protein. These results indicated that the mechanisms of 
these antisense oligonucleotides involved the inhibition of both 
transcription and translation. 
4.8 Further Directions 
Synthetic nucleic acids interfering with gene expression are 
being developed as specific regulators of gene expression both for 
fundamental studies and for medical applications. Although 
straightforward in principle, the approach still faces many 
unknowns. Cell-free studies with model systems will help to learn 
much about the various modes through which oligonucleotides bind 
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to their nucleic acids. Increasing numbers of modifications allowing 
improved resistance toward nucleases or more efficient interaction 
with various targets have been devised and more will be 
forthcoming. 
In the future, the concern will be concentrated on the action 
mechanism. Although anti-GLUT 1 oligonucleotides and expressed 
nucleotides can inhibit the cell proliferation of HL-60, the underlying 
mechanism is not fully known. As anti-GLUT 1 antibody is already 
in the market, Western Hybridization can be performed, as another 
approach, to confirm the decrease in GLUT 1 protein after treating 
by antisense nucleic acids. 
Moving to in vivo experiments as a prelude to possible 
applications in humans will be the next step. As GLUT 1 appear in 
almost all cell types, targeting the antisense nucleic acids to specific 
cancer cells without affecting other normal cells is an urgent task. 
One of the methods is to link the liposome to an antibody that is 
specific to the antigen on cancer cells QVLaruyama et al., 1995). This 
liposome then encapsulates the antisense nucleic acids and carries 
them to the cancer cells. 
The oligonucleotide uptake efficiency can be further improved 
by using liposomes of different formulations. The nature and 
proportion of ionic compound and lipid in liposome can be varied 
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depending on cancer cell types and oligonucleotide modification to 
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